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CHAPTER 1 INTRODUCTION
The second leading cause of death in the United States is cancer; responsible for 591,666 or
22.53% of deaths in 20141. Although the number of cancer deaths continue to increase each year, the
percentage of deaths caused by cancer has fallen 12% over the past decade 2. Data from the American
Cancer Society shows that number of cancer deaths that are prevented each year has grown steadily since
19913. One of the main drivers in improved cancer survival is the increase in computing power over the
past decades, allowing for improved diagnosis techniques, characterization of individual cancers, and
more complex treatments. As the diagnosis-treatment paradigm grows more complex, research tends to
focus on subsets of the entire process.
The study of diagnosing and treating cancer begins with an examination of the human body, which
exists in a homeostatic state with cells constantly dying (apoptosis, autophagy, etc.) and multiplying
(mitosis). The balance of this state relies on the rate at which cell death and mitosis occur. Too much cell
death and the body dies. Conversely, an uncontrolled high rate of mitosis leads to cancer. The goal of
cancer therapies is then to move the body back towards a homeostatic state by killing the fast growing
cancerous cells, while preserving the controlled cell growth of the normal tissue.
Amongst other cancer fighting techniques, radiation can be used to kill cancer cells. High energy
radiation has the potential to ionize atoms within the body, causing fundamental damage to the cell and
ultimately cell death. One issue with radiation is that it is indiscriminate towards cancerous and healthy
cells. However, the cells themselves respond differently to radiation exposure. In the context of radiation
therapy the groups of cells are looked at macroscopically. For cancerous cells this equates to tumor
growth and for normal tissue this equates to physiological tissue or organ function. When radiation
therapy is delivered the goal is to control tumor growth and limit the degradation in physiological
functionality.
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Figure 1: TCP and NTCP models showing tissue response to radiation. Also plotted is the probability of
tumor control without complications.
Two terms are commonly used to describe the tumor and normal tissue response during radiation
therapy:
1) tumor control probability (TCP) – “The probability that a given dose of radiation will provide
tumor control or eradication considering the specific biological cells of the tumor.”4
2) normal tissue complication probability (NTCP) – “The probability that a given dose of radiation
will cause an organ or structure to experience complications considering the specific biological cells of the
organ or structure.”4
These two terms are derived from concepts regarding the number of proliferating cells surviving after
irradiation, which is typically modelled with a Poisson like distribution5. Figure 1 shows a hypothetical
example of the two probabilities plotted as a function of radiation dose. Within the two curves a region
exists known as the therapeutic window, where dose is sufficient to control the tumor (high TCP), while
sparing normal tissue (low NTCP). This region can best be seen by examining by plotting the probability
of tumor control without complications ( TCP * [ 1 – NTCP] ).
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In this simple example, the radiation therapy treatment would administer dose within this
therapeutic window; the tumor would be controlled and the patient would not experience any side
effects. However, the treatment becomes more complicated when patient-specific uncertainties are
included within the figure. For an individual patient, the TCP and NTCP curves change from precise lines
into probability distributions. Furthermore, the delivery of radiation dose itself is not exact, creating a
third probably distribution. The result is that it becomes more difficult to administer dose within the
therapeutic window.
Different techniques have been used to increase the chances of a successful treatment, including:
widening the gap between the NTCP and TCP curves, and increasing the precision of the curves and the
delivered dose. The TCP curves can be shifted to lower doses by combining radiation therapy with other
forms of treatment (ex. chemotherapy, hormonotherapy, etc.). NTCP curves can be shifted to higher doses
by delivery more conformal treatments, so that a given dose or radiation to the tumor delivers less dose
to the surrounding tissue.
While widening the therapeutic window is an important part of radiotherapy research, this work
focuses on increasing the precision of the delivered dose. As mentioned at the beginning, the diagnosistreatment paradigm is quite complex, so it would be difficult to tackle the issue of precision from start to
finish. A more attainable approach was used in this research by breaking the process into subsets and
making focused improvements to increase the precision of the entire process. In the coming sections, the
treatment process will be briefly outlined and broken into individual subsets for potential improvement
in dose delivery precision.
There are three different types of radiation therapy:
1) Internal - temporary or permanent radioactive sources are implanted into the patient.
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2) Systemic - radionuclide injections or oral administrations are given to the patient that spread
throughout the entire body.
3) External - high energy beams are generated outside the body and directed toward the patient.
External beam radiation therapy is the most common treatment method. The technique involves
generating radiation beams, with high enough energy to ionize atoms, and then directing them within the
body. These beams can be comprised of electrons, photons, protons, neutrons, and other heaving ions.
This research was focused on an advanced form of photon treatment called Intensity Modulated Radiation
Therapy (IMRT).
IMRT is type of photon treatment that uses beams with spatially modulated dose distributions6.
The technique improves upon the traditional 3-dimensional method of treating with uniform dose fields.
Whereas 3D techniques create dose distributions that resemble simple geometric shapes (Figure 2A),
IMRT treatments can contain more complex distributions that conform to the cancer and better spare
normal tissue (Figure 2B). Due to the complexity of IMRT, an inverse planning method is often employed
where a computer is given dosimetric objectives and an optimization algorithm is used to determine
optimal beam parameters7-9. Conversely, 3D treatments are created using forward planning where beam
parameters are set manually to achieve given dosimetric objectives10. IMRT was first proposed in the
1980’s11. However, due to inverse planning’s requirement for computing power, it is not surprising that
the development of IMRT coincided with the technological advancement of computers in the mid
1990’s12.
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(A)

(B)
Figure 2: Isodose line comparison between 3D (A) and IMRT (B) treatment techniques. IMRT isodose lines
better conform to the target (red), while avoiding the normal tissue (green).

Over the past two decades, IMRT techniques have continued to evolve. PubMed articles with the
term “Intensity Modulated Radiation Therapy” in the title have been steadily increasing (Figure 3)13.
Fueled by research, countless commercial solutions have been created providing clinical solutions for
IMRT. Although the clinical solutions are diverse, the process for treating patients with IMRT is somewhat
standardized.
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Figure 3: Number of PubMed articles with the term "Intensity Modulated Radiation Therapy" in the title.
The patient’s treatment begins with a computed tomography (CT) scan to localize the tumor and
normal tissue within the body. Commercial CT scanners provide multiple scanning options that typically
include contrast-coincident scans for better organ delineation14, reconstruction algorithms for artifact
reduction and better image quality15-18, 4D imaging capabilities to capture anatomy during cyclical
physiological functions19. The end result is a CT, or series of CTs in the case of 4D imaging, which is sent to
a treatment planning system (TPS) to design the therapy delivery.
Various commercial treatment planning systems are available for clinical use. Planning systems
can be specific to a particular delivery system20-22, specific to a treatment site20, 23, or general planning
solutions24-30. Apart from cosmetic differences, each planning system has their own solution for dose
calculation and optimization. Dose calculation engines focus on speed and accuracy. Early dose engines
were simple, often sacrificing accuracy for speed31-33. Developments in computing power and GPU-based
computing34, 35 have led to the clinical adaptation of more accurate dose engines36, 37. Optimization
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algorithms focus on speed and flexibility to achieve acceptable solutions. A wide range of solutions exist
for generating the optimization paramters38, 39, performing the optimization40; evaluating and modifying
the optimized solution41. Whatever technique is used, the TPS will generate a treatment plan that dictates
how the delivery system should administer radiation to the patient.
The treatment plan generated by the TPS must conform to the physical limitations of the delivery
systems. Perhaps the most important of those limitations is that of the multi-leaf collimator (MLC), which
is responsible for creating the field modulation that characterizes an IMRT delivery. Various MLC designs
exist, however they typically consist of independently moving collimating leaves responsible for radiation
attenuation (Figure 4)42-44. Optimization algorithms contain checks to ensure plan deliverability, however
due to complexity of the delivery system, an on-line check of the plan deliverability is often performed
prior to the patient treatment.

(A)

(B)

Figure 4: Two examples of commercial MLCs. A) Varian’s 120 Leaf Millennium MLC, B) Elekta’s 160 leaf
Agility MLC.
The pre-treatment checks, colloquially referred to as IMRT QA, are typically performed by
delivering the plan to devices that measure absolute and relative spatial dose distribution. The measured
dose is compared to that predicted by the TPS to determine whether the treatment machine can
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accurately deliver the plan generated by the TPS. The devices used to measure dose and the comparative
methods are as diverse as the delivery and TPS systems themselves.
Historically, point dose measurements were performed with ion chambers45, while spatial dose
distributions were measured with radiographic film46. Ion chambers remain the gold standard for dose
measurements, however the use of film has declined. Radiographic film requires dark rooms and chemical
processors. The processing itself is sensitive to chemical composition and temperature, creating day-today variations in film response47. These shortcomings were overcome with the advent of processor-free
radiochromic film48. Even without processing, Radiochromic film still requires the time consuming step of
scanning prior to analysis.
Film is still in use today for precise stereotactic measurements as it offers the highest resolution
of any dosimeter (sub-millimeter)48, however real-time measuring devices have been widely adopted for
routine IMRT QA. These devices are comprised of multi-detector arrays imbedded in water equivalent
material. Geometries of the arrays, shown in Figure 5: IMRT QA measuring devices: A) Single plane liquid
filled chambers, B) Orthogonal plane diode array, C) Cylindrical diode array, differ from single planes49-53,
to orthogonal planes54, and cylindrical55 configurations. Various detectors including open-air50, 53 and
liquid filled ion chambers51, diodes49, 54, 55, and EPIDs52 have all been used. All detectors are connected to
electrometers and computer software, which give direct readouts of the measurements and allow for fast
comparison to the TPS.
Point dose measurements are compared to the TPS using a simple normalized difference formula.
Conversely, planar dose measurements are compared to the TPS using more complex analysis techniques;
the most popular of which is the Gamma Index. The Gamma Index combines dose differences with
distance criteria to compare each individual detector measurement to the corresponding surrounding
dose predicted by the TPS56. The Gamma Index itself is customizable by varying the analysis criteria57, 58,
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measurements included in the analysis59, 60, and normalization methods61. In addition to the Gamma
Index, other solutions have been developed that use different combinations of dose differences and
distances to compare measurement planes to the TPS62. These analysis techniques have also been
extended into three-dimension space to analyze 3D-dose reconstructions from planar measurements63,
64

. Other pre-treatment checks analyze machine log files to check if the machine is in the correct state

throughout the delivery65. Regardless of the pre-treatment check, if the results of the analysis meet a predetermined threshold criteria, the treatment plan is deemed acceptable for delivery.

(A)

(B)

(C)

Figure 5: IMRT QA measuring devices: A) Single plane liquid filled chambers, B) Orthogonal plane diode
array, C) Cylindrical diode array.
When delivering IMRT treatments to patients, the focus is on dosimetric accuracy to ensure
treatment falls within the therapeutic window. Dosimetric accuracy relies on positioning the patient and
the treatment volume in the same position as was planned in the TPS. The two major concerns with
positioning are interfraction and intrafraction motion.
Interfraction motion can be caused by voluntary or involuntary motion. Voluntary motion occurs
when a patient shifts position during treatment, usually due to discomfort. The first line of defense against
voluntary motion is watching the patient outside the treatment room and halting the treatment if
movement occurs. State and federal regulations mandate that the patients are monitored at all times,
making this a necessity for all treatments. While gross patient movement are easily visible, small
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movements are more difficult to detect. Small motion detection has been accomplished with systems that
track patient anatomy66, and internal67 or external fiducial markers68.
Although monitoring and detecting voluntary motion is important, prevention is usually sufficient
for most treatments. To help prevent voluntary motion, immobilization devices have been designed,
which place the patient in a comfortable position, while creating the most unobstructed path for the
radiation to reach the target69. These devices are designed to be mostly radio-transparent, however
beams passing through them can still be perturbed, causing dosimetric differences in the treatment70.
A well immobilized patient will still have involuntary motion due to normal autonomic functions
(breathing, heartbeat, etc.). One method to account for this motion, is to treat a larger volume, ensuring
that regardless of the instantaneous phase of the autonomous motion, the tumor remains in the target
area71, 72. The obvious issue is that this also delivers more dose to the normal tissue, reducing the
therapeutic window. A less intuitive issue occurs with IMRT, due to the modulated nature of the fields
and the harmonic nature of respiratory motion. Commonly referred to as the interplay effect, it occurs
when the tumor moves into one area of the treatment volume, when the IMRT field is delivering the dose
elsewhere within the target73. This effect can be mitigated by using lower dose rates and larger aperture
sizes74, 75.
The treatment volume can also be reduced by minimizing tumor motion or gating the treatment.
Motion can be reduced through compression76 and breath control, both forced77 and voluntary78.
Compression reduces tidal volume and the magnitude of tumor motion. Breath control has the patient
pause during a specified respiratory phase (typically inspiration), which effectively eliminates respiratoryinduced motion. Gating creates a window within the respiratory cycle where the beam will turn on, and
can be used in parallel with breath hold or as a standalone technique79.
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While all these tools are useful for preventing intrafraction motion, the largest deviations can
occur with the interfraction motion. Patient setups will naturally vary on a day-to-day basis, and can grow
in magnitude from responses to treatment, such as weight loss, tissue irritation, and reduction in tumor
volume. The immobilization devices that help to prevent intrafraction motion, will also provide a stable
platform for reproducible interfraction setups. However, deviations are expected, therefore some form
of pretreatment on-line imaging is typically performed to verify the correct patient position.
The on-line imaging systems consist of various combinations of planar radiographs, CTs80, 81, RF
trackers82, ultrasound83, and more recently MRIs84. Each system acquires information regarding the
patient’s position, which it compares to reference data generated from the planning CT. If a minor
discrepancy is observed, the delivery systems are able to perform linear and rotation adjustments via
robotic couches85, 86 or delivery adjustments87. Major adjustment require manual repositioning of the
patient or a re-simulation and a new plan. Once adjustments are made, and the patient is located in the
correct position, the delivery is initiated and the aforementioned intrafraction positioning systems are
used to monitor the patient.
From start-to-finish, an IMRT treatment involves many different sub-systems within a
department. To ensure the entire system is functioning properly prior to treating the first patient, a
lengthy commissioning process occurs. Multiple task group reports from the American Association of
Physicists in Medicine (AAPM) have been published that outline recommended procedures for
commissioning and ongoing quality assurance in a radiotherapy clinic6, 18, 19, 88-109. These reports address
the commissioning of treatment techniques of varying complexity, starting from simple 3D treatments, to
the most advanced stereotactic radio surgery (SRS) cases. A subset of these reports focus specifically on
IMRT6, 91, 96. However, all of the reports should be considered when designing an IMRT commissioning
process.
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Generally, the commissioning tests that are performed specifically for IMRT implementation
include: point dose measurements, planar measurements, TPS test patterns, MLC QA, end-to-end testing,
and external credentialing. Although these tests are performed differently between institutions, the
overall goal is to ensure accurate delivery of radiation through highly modulated and possibly moving MLC
apertures.
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Figure 6: Measured dose from two differently size detectors compared with the true dose. Volume
averaging increases with detector size.

The high degree of modulation may result in small aperture sizes, which could require specific
point dose measurements for the TPS. These measurements are often more difficult than their large-field
counterparts, as additional small field effects occur. The most common small field effect is volume
averaging, which occurs when the detector size is on the same order of the measured dose feature110. As
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the name suggests, the detector volume will tend to average the dose distribution causing an overall
smoothing effect. An example of volume averaging is shown in Figure 6. For a field size (FWHM) of 15mm,
a 2mm detector shows minor signs of volume averaging and the effect is prominently visible for a 5mm
detector.
Other small field effects include: partial source shielding causing an overestimation of field size
when using traditional FWHM metrics and a loss in charge particle equilibrium causing a change in
detector response. All of these effects are sensitive to the detector selection and experimental setup111.
One method that is used to account for these effects, is to perform Monte Carlo simulations to generate
correction factors112. However, these simulations are complicated and must be done for each detector
and each setup, making them unrealistic for ad hoc clinical measurements. Therefore, clinical
measurements are often performed using a “daisy-chain” method, whereby different detectors are
calibrated in sequentially smaller fields, and the measurements are referenced back to a precise large
field dose measurement113. These corrections can often become more difficult for planar dose
measurements when a detector under a moving MLC aperture may have a changing response.
In addition to small field planar measurements, IMRT commissioning involves a thorough analysis
of dosimetric distributions surrounding the MLCs in large fields as well. The ability of the MLC leaves to
move independently means often times an MLC leaf will extend into the middle of the field. As a result,
the dosimetric penumbra from the leaf tip and leaf sides, as well as the transmission through the leaf, will
have a greater effect on the high dose region of a field compared with a 3D treatment. Therefore, much
more time is spent accurately modeling the MLC during commissioning. This typically involves
measurements of more complex beam apertures which are compared to the TPS predicted dose.
Once the TPS modeling is complete, it is recommended to perform an end-to-end (E2E) test, which
simulates the entire patient experience from simulation to treatment. E2E tests can either be analyzed
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internally or externally. When the analysis is performed externally, an outside institution or company will
send the clinic a phantom embedded with dosimeters (Figure 7) . The commissioning institution will
acquire a CT of the phantom, plan an IMRT case to meet certain objectives, perform QA testing for the
plan, deliver the plan to the phantom, and send the phantom and TPS dose back to the outside group.
The outside group will process the phantom dosimeters and compare the measurements to the TPS dose.
The qualitative results will be reported back to the institution. In some cases, they will also report a pass
or fail result depending on how closely the measurements match the TPS.

(A)

(B)

(C)

Figure 7: IROC Houston H&N Phantom. TLD measurement devices shown in color. A) Axial, B) sagittal, C)
coronal planes.
This external analysis is important as it provides an independent check of an institution’s
processes and equipment. To ensure that institutions participating in clinical trials meet a minimum
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delivery accuracy, the National Cancer Institute (NCI) requires that these tests be passed, prior to
participating in radiation oncology clinical trials114. The Imaging and Radiation Oncology Core (IROC) in
Houston, formerly known as the Radiological Physics Center, is one such group who provides these
external E2E checks. A CT image of their H&N phantom is shown in Figure 7. They have published statistics
of the passing rates for their tests, which show the difficulty in IMRT commissioning115. For example, in
2003, approximately 64% of the tests had a passing result. Fortunately, the cumulative passing rate rose
steadily over the next ten years to a value of approximately 83%. The increase in pass rates was likely due
to the increased familiarity with IMRT, and the availability of guidance documents. However, even with
the increased pass rates, the number of institutions which still failed the test in 2013 was 11.5%, which
highlights the difficulty in accurate IMRT dose delivery.
A major drawback to the external analysis is the delay in receiving results. Most institutions will
also perform their own E2E tests with an internal analysis, providing immediate results, which are then
used to guide commissioning. Only after rigorous internal testing is completed, the external test is
performed. To provide guidance for clinical physicists performing these internal tests, AAPM TG Report
No. 119 was published96. Distributed with the publication is a set of CTs and structure sets for a
standardized solid water phantom, which is typically available in Radiation Oncology clinics. An example
of these structures is shown in Figure 2. IMRT plans are created on the CTs using planning objectives
provided in TG 119. After plan generation, IMRT QA is performed using the recommended analysis and
compared against other institutions results, which are published in the report. This allows a physicist to
easily determine how their commissioning results compare with other institutions.
In addition to having a thorough commissioning process, routine QA of the delivery machine must
be performed to ensure accurately delivery. Unlike the E2E tests which attempt to quantify the overall
accuracy of the system, routine QA attempts to isolate individual components for testing. These routine
QA tests are a subset of the commissioning tests, whose scope is designed to detect typical malfunctions
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of the delivery system. AAPM TG Report No. 142 contains a comprehensive list of recommend tests and
suggested passing tolerances95. The tolerances become tighter as delivery complexity increases, and
increased precision is required. The overall goal is to maintain the same delivery accuracy as
commissioning throughout the lifetime of the machine.
To maintain a high degree of accuracy for an IMRT delivery, uncertainties must be minimized
throughout the commissioning, routine QA, simulation, planning, IMRT QA, setup, and delivery processes.
The goal of this research was to look for subsets of the process for possible improvement. This work
focused on research in these five areas:
1) Radiation-Imaging coincidence optimization: on-line imaging systems are calibrated to match
the radiation center of the treatment machine. However, the radiation center will drift within the patient
depending on the selection of machine parameters (mechanical settings and energy selection). A
mismatch between the imaging and radiation centers will introduce uncertainty into the IMRT delivery.
While this uncertainty cannot be completely eliminated, the imaging systems and radiation machines can
be calibrated to reduce the uncertainty, thereby improving the radiation-imaging coincidence. A
procedure was developed to optimize the radiation-imaging coincidence for an Elekta Versa HD (Elekta
AB, Stockholm, Sweden) during commissioning. The procedural steps, along with their limitations, will

be discussed.
2) End-to-end testing using AAPM Task Group No. 119 – The conclusion of this report relied on
statistics calculated from the consortium data. Specifically, the data was modelled as a Gaussian
distribution with an unrestricted domain. However, the data consisted of pass rates that were naturally
truncated at 100%. Furthermore, the pass rates may be better modelled by a statistical distribution which
is tailored to approximate failure data. Therefore, the accuracy of the statistical technique used to
compare institutional results with the published consortium data was scrutinized.
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3) IMRT QA Measurements – PTW’s 1000 SRS device uses an array of liquid filled ionization
chambers for measurements. Due to the lower ion mobility in the liquid compared with air-filled
chambers, the 1000 SRS has increased ion recombination. The recombination is dependent on radiation
pulse strength and duration. As the pulse characteristics change during an IMRT delivery, so too will the
response of the detectors. The changing response of the detectors may lead to inaccurate measurements.
The effect of changing detector response on IMRT QA measurements using the 1000 SRS was investigated.
4) IMRT QA Analysis – Typical Gamma Index calculations use a uniform set of passing criteria to
analyze an entire measurement. The result is that all treatment areas and normal tissue are considered
equally important during the analysis. However, clinical IMRT cases typically have one or two normal
tissues with an expected dose on the edge of therapeutic window. Dosimetric accuracy is more critical for
these tissues to prevent complications. The possibility of varying Gamma Index calculations across the
field, specifically by using information taken from patient anatomical structures, was investigated.
5) IMRT cranial SRS commissioning: Brainlab’s (Brainlab, Munich, Germany) Elements Multiple
Brain Mets SRS (MBMS) is a dedicated treatment planning system for single-isocenter multi-target (SIMT)
cranial stereotactic radiosurgery (SRS) treatments. Characterized by small treatment margins,
hypofractionation, and large dose gradients, SRS treatments are a sub-class of IMRT deliveries that are
perhaps the most sensitive to uncertainties throughout the commissioning to treatment process. The
purpose of this work is to present the commissioning experience of MBMS on an Elekta Versa HD. The
experience presented can be used to aid the future commissioning of Versa HDs in the Brainlab MBMS
treatment planning system, to produce safe and accurate SIMT cranial SRS treatments.

18
CHAPTER 2 RADIATION-IMAGING COINCIDENCE OPTIMIZATION ON A VERSA HD
Introduction
The utilization rate for linac-based stereotactic body radiation therapy (SBRT) and stereotactic
radiosurgery (SRS) for cancer treatment has increased throughout the 21st century.116-119 Characterized by
conformal doses and small margins, SBRT/SRS treatments are able to deliver precise doses to targets in
fewer fractions compared with conventional radiotherapy options.93 Medical physics practice guidelines
address the need for heightened precision by creating tighter tolerances for machines that are being used
for SRS/SBRT.120 One such tolerance is the requirement that the on-board imaging system, used to align
the patient, coincide with the radiation isocenter within 1mm. Borzov et al. have shown that the +/-1.0mm
tolerance is reasonable to preserve the dosimetric delivery accuracy of SRS/SBRT121.
Achieving coincidence of the radiation and imaging isocenter can be challenging on modern linear
accelerators. This is due to the multiple photon energies available as well as the ability to use flattening
filter free beams which must all coincide with a single imaging isocenter. Cross-energy calibration on
Elekta’s Versa HD (Elekta AB, Stockholm, Sweden) is of particular importance due to its larger gantry sag
of 1.0mm compared with 0.5mm on Varian’s TrueBeam (Varian Medical Systems, Pal Alto, CA). 122-125 The
isocenter movement of 1.0mm on the Versa HD corresponds to a +/-0.5mm drift in radiation isocenter,
which amounts to half the 1.0mm tolerance of the radiation-imaging isocenter coincidence for SRS/SBRT.
Zhang et al. attempted to reduce the spread between the energies on an Elekta Versa HD using software
included with the linac (Flexmap Wizard) to guide beam steering.126 They were able to achieve radiationimaging coincidence of less than 1.5mm for all energies, which was within their clinical tolerance.
Part of the difficulty in achieving a <1.0mm radiation-imaging isocenter coincidence across all
energies is that this specification is not guaranteed by the linac manufacturers, and as such, there is no
formal calibration procedure. With no direction from the vendors, it is left to physicists to develop a
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procedure. In clinical practice, this calibration is best implemented with the installation engineer, prior to
acceptance. However, there can often be hesitation from the installation engineer when asked to perform
a calibration outside their agreed upon scope of work. Furthermore, if the physicist is unfamiliar with the
procedure and its associated limitations, it may result in the physicist asking the engineer to achieve
unrealistic tolerances. Therefore, in this work a formal procedure was developed to perform cross-energy
isocenter calibrations during Versa HD installations. The cross-energy calibrations were performed along
with couch and imaging calibrations to reduce the overall radiation-imaging isocentricity of the Versa HD
and this procedure along with its limitations is discussed.
Materials and Methods
Calibration of the total radiation-imaging isocentricity of a machine is done by calibrating
individual components. The following terms will be used to describe these individual components
throughout this procedure:
1) Radiation beam center: center of the radiation beam that is dictated by where the electron source
beam strikes the photon-generating target.
2) Collimator rotation axis: mechanical center of the collimator rotation.
3) Linac isocenter: average radiation center of a beam over all gantry and collimator rotations.
4) Couch rotation axis: mechanical center of the couch rotation.
5) Imaging isocenter: location of imaging system center or isocenter calibration and laser calibration.
In this procedure the radiation beam centers were adjusted to match the collimator rotation axis, followed
by a calibration of the imaging isocenter to match the linac isocenter, and finally the couch rotation axis
was adjusted to match the linac isocenter.
Prior to adjusting the radiation beam centers to match the collimator rotation axis, the linac was
calibrated closely to its final geometric and beam settings during initial customer acceptance testing.
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Briefly this included: adjusting percent depth doses (PDDs), profiles, collimator runout, and calibrating the
MLCs and jaws to within the installation customer acceptance specifications. Importantly, the collimator
mechanical isocentricity was tested and the collimating head, where the MLCs and jaws are mounted to
the gantry, was adjusted to be within installation tolerances. With the linac close to clinical settings, the
beam centers of each energy were steered to match the collimator rotation axis.
Steering Radiation Beam Centers to Match Collimator Rotation Axis
At this point in a traditional linac calibration, beam center steering would be performed with a
half-beam block (HBB) test. The HBB setup would consist of taping a cylindrical ion chamber (e.g. Farmertype ion chamber) in the gun-target direction to a block tray at the central axis of collimator rotation
(Figure 8A) for an off-center 10x10 cm2 field. The central axis of the farmer chamber is placed on the lightfield crosshairs; small misalignments of the farmer chamber will not affect the overall result. One jaw is
closed to the central axis to cover half of the field in either the gun or target direction and the opposing
jaw remains open (Figure 8B). A voltage is applied to the farmer chamber, 100MU is delivered with the
collimator at 0 degrees, and the resulting charge reading is recorded. The collimator is rotated 180 degrees
and the measurement is repeated. If the radiation beam center was perfectly aligned with the collimator
rotation axis then, these two measurements would be the same.
If the two measurements were different, an adjustment would be needed to the beam center to
align it with the collimator rotation axis. This would typically be done by changing the current in the
steering coils (adjusting bending fine on a Versa HD), which moves the location where the electron beam
strikes the target and consequently the center of the resulting photon beam. After adjustments, the HBB
test would be repeated until the two measurements agree within some threshold (<0.5% is often used).
Some drawbacks to the HBB measurements are that these adjustments can be time consuming and will
not give quantitative information of the distance between the beam centers and collimator axis. These

21
drawbacks will become exacerbated when performing the HBB test for the five photon energies on the
Versa HD.

Figure 8: Half Beam Block (HBB) setup for steering beam centers. (A) Farmer chamber is taped on a block
tray at the central axis in the GT direction, (B) the collimator is closed to the central axis to block half the
field.
In the proposed linac calibration, to reduce the beam steering time and provide quantitative
information regarding the distance from the beam centers to the collimator axis, a second test, a modified
version of the Winston-Lutz test using only images at gantry, couch, and collimator angles of 0 degrees,
was introduced into the calibration procedure.127-129 By analyzing the Winston-Lutz images, the deviation
between a BB, placed in the field, and the radiation beam centers could be determined (henceforth known
as the BB-beam center deviation). The goal was to collect HBB measurements and BB-beam center
deviations for various values of bending fine and correlate the results of the two tests to find the ideal
bending fine settings needed for the BB-beam center deviation to match the HBB measurements.
Adjustment could then be made to bending fine and the BB-beam center deviation could quickly be remeasured to providing quantitative information of the radiation-collimator alignment.
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First, a HBB measurement was performed, using a Standard Imaging (Middleton, WI) Exradin A12
Farmer-type ion chamber, for all five photon energies at collimator angle 0 degrees without performing
any beam adjustments. Next, four additional measurements were acquired for each energy with the
bending fine parameter adjusted +/- 0.1 and +/- 0.2 around the starting value. To quickly change bending
fine, without affecting the stored clinical beam, a 100MU beam should be started and quickly interrupted
during the initial ~1 second warm-up period prior to any delivery of radiation. Then the bending fine
parameter can be changed on the steering page, and the beam will be delivered with the new bending
fine parameter. After delivery, the beam will revert to its original stored value for bending fine. After
acquiring 5 HBB measurements at collimator 0 degrees for each photon energy, the collimator was rotated
180 degrees and the measurements were repeated. Finally, the HBB percent differences between 0 and
180 degrees was calculated for each energy and bending fine setting for a total of twenty-five results for
the five photon energies.
Next, the HBB setup was completely removed, and a BB was placed close to collimator-axis using
the light-field crosshairs as a guide. A square field was used to acquire portal images of the BB on the
Versa HDs on-board MV imaging system (iView) at gantry and collimator angles of 0 degrees. Twenty-five
portal images with the various energies and bending fine parameters to match the HBB measurements.
After each portal image, the beams revert to their original stored value for bending fine as described in
the previous paragraph. The portal images were exported to Sun Nuclear’s SNC machine v1.3 (Sun Nuclear
Corporation, Melbourne, FL) software as DICOM files, which processed the portal images to determine
the BB-beam center deviation for each image.
The deviations in the gun-target direction were plotted against the results of the HBB test for the
five energies and modelled with a linear regression (Figure 9). From the definition of the HBB test, if the
difference between the two HBB measurements (for collimator 0 and 180 degrees) is zero percent, the
beam is perfectly aligned with the collimator axis. Therefore, the linear regression can be solved to
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determine the desired BB-beam center deviation needed to achieve perfect alignment between the beam
centers and collimator rotation axis. It is important to note, that if the BB was perfectly placed at the
collimator rotation axis, the desired BB-beam center deviation would be a distance of 0.0mm. However,
since the BB was placed close to the collimator rotation axis using the light field, the desired BB-beam
center deviation to achieve perfect radiation-collimator alignment will likely be non-zero. As the BB will
likely not be placed perfectly at the collimator rotation axis, no adjustment should be made to the
collimating jaws to match the BB position. In this instance, the average desired BB-beam center deviation
over all energies, corresponding to a HBB measurement of zero percent, was 0.87mm (Figure 9).
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Figure 9: Correlating Half Beam Block (HBB) measurements with BB-beam center deviation results in the
gun-target (GT) direction for Versa HD photon energies (6X, 10X, 15X, 6FFF, and 10FFF). The 0.0% HBB
result corresponding to 0.87mm is the desired BB-beam center GT deviation.
To adjust the beam centers to match the collimator rotation axis, the bending magnets were
adjusted by the service engineer using the “bending fine” setting on the linac, and another portal image
was acquired and processed using SNC Machine. This procedure was repeated until the SNC Machine
reported BB-beam center deviation in the gun-target (GT) direction was sufficiently close to the ideal value
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determined from the linear regression (0.87mm for this calibration). After bending fine adjustments, the
BB was removed, and the symmetry of the beam was checked using Sun Nuclear’s IC Profiler (Sun Nuclear
Corporation, Melbourne, FL). If large adjustments in bending fine are made for a given energy, a
corresponding symmetry adjustment may be necessary.
Calibrating Imaging Isocenter to Match Linac Isocenter
Following the profile symmetry checks, the BB was placed back near isocenter using the light field
and a 3-dimensional WL test was performed for all energies to determine their respective linac isocenters.
This test utilized the Elekta provided Flexmap Wizard beam sequence, which included portal images at
the four cardinal gantry angles with two collimator angles, 180 degrees apart, for a total of 8 portal
images. The different gantry angles were needed to account for gantry sag, while the collimator angles
were needed to nullify the effects of collimator misalignment. All portal images were acquired using iView
and processed through SNC Machine, which computed the offset between the BB and linac isocenter for
each energy.
With the linac isocenter position for each photon energy determined, it was decided to calibrate
the lasers and kV imaging system to the average of all the energies. Some other possible options include
calibrating to the average of the energies used for SRS/SBRT, or the most used energies. In this work, the
average position was selected to determine the overall radiation-imaging isocentricity achievable across
all energies simultaneously.
Once the selection was made, micrometers on the Elekta provided BB jig were used to move the
BB to the average linac isocenter position using the shifts derived from SNC Machine. Additional 8-field
WL portal images were acquired and processed through SNC Machine to ensure the BB was moved
correctly relative to its original location. After verifying the BB was in the correct location, the Elekta
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Flexmap Wizard was run to calibrate the imaging isocenter to the BB location, which corresponds to the
average linac isocenter location for all photon energies.
After imaging calibration, the lasers were adjusted to match the external lines on the BB jig. It
should be noted that the lines on the BB jig may not be perfectly aligned to the BB. When the BB jig is
initially delivered to the facility, it is recommended to place small copper wires on the external lines and
acquire kV images using either the kV imager on the Versa HD or topograms from a department CT. The
wires and BBs will both be visible on the planar images and the wire overlap at the centroid of the BB can
be evaluated.
Adjusting Couch Rotation Axis to Match Linac Isocenter
The last step in the procedure was to adjust the couch rotation axis to match the linac isocenter.
The location of the current couch rotation axis relative to the radiation-gantry isocenter was determined
by performing a specialized Hancock WL test that is included in SNC Machine. The Hancock WL test
involved acquiring twelve WL images with a specific combination of gantry, collimator, and couch
rotations (5 couch angles were used: 270, 315, 0, 45, 90 degrees). SNC Machine was used to analyze these
portal images and it returned a report that states the offset between the couch rotation axis and linac
isocenter. The reader is referred to the Sun Nuclear manuals for full details on how the software uses the
portal images to calculate couch offset.
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Figure 10: Versa HD couch schematic showing the location of adjustment bolts A & B. The gun (G) and
target (T) directions are also labeled, while the up (U) and down (D) directions are not shown.
Alternatively, a couch runout test could have been performed by projecting the lasers (now
calibrated to linac isocenter) onto a piece of paper on the couch and marking the laser position at various
couch angles. If there is a deviation between the couch rotation axis and linac isocenter, the laser will
trace a semicircle about the couch rotation axis.
The couch rotation axis was matched to the linac isocenter position by adjusting the couch
support system. The couch sits on top of a tripod support system shown in Figure 10. The couch rotation
axis was adjusted by turning the two bolts closest to the gantry according to Equations (1a) and (2b).
Similar equations for other couch types can be derived through theoretical calculations or empirical
testing. After the couch was adjusted, the BB was repositioned at the linac isocenter using an 8-field WL
test, and the Hancock WL test was re-run until the coincidence between the couch rotation axis and linac
isocenter was satisfactory.

A Bolt turns = (10.88 Table X – 10.48 Table Y) flats/cm

(1a)

B Bolt turns = - (10.88 Table X – 10.48 Table Y) flats/cm

(2b)
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Measuring Radiation-Imaging Isocentricity
Finally, the radiation-imaging isocentricity of the system was characterized by analyzing WL portal
images acquired at a subset of combinations of gantry, couch, collimator, and photon energies that were
to be used for SRS/SBRT treatments with the BB located at imaging isocenter. In total, 18 combinations
of gantry, collimator, and table (GCT) positions were performed: G180C270T0, G180C0T0, G180C90T0,
G270C270T0, G270C0T0, G270C90T0, G0C270T0, G0C0T0, G0C45T0, G0C90T0, G0C315T0, G90C270T0,
G90C0T0, G90C90T0, G0C0T45, G0C0T90C0, G0C0T315, G0C0T270. Additionally, the isocentricity was
calculated for the following combinations of gantry, collimator, and table (GCT) positions: G180C0T45,
G180C0T90, G180C0T315, G180C0T270. Since the number of permutations that need to be tested can
become large, a smaller subset can be chosen for analysis according to clinical requirements. All WL portal
images were acquired using iView and processed through SNC Machine to determine the deviation
between the center of the BB and the center of the radiation field. The deviations in both directions of
the image were combined to determine the Euclidian distance between the BB and the radiation field.
The overall radiation-imaging isocentricity was specified as the largest Euclidian distance in any image for
a given energy.
Results
The results of the bending fine adjustment along with corresponding changes to the beam center
position are shown in Figure 11. The ideal location for the BB, obtained from Figure 9, was 0.87mm. All
beams were calibrated within 0.10mm of the collimator rotation axis.
For future measurements, the slopes of the correlations in Figure 11 can be used to estimate the
necessary change in bending fine (BF) needed to adjust the beam center for each photon energy: 6X:
0.55BF/mm, 6FFF: 0.50BF/mm, 10FFF: 0.58BF/mm, 15X: 0.75BF/mm. Bending fine adjustment was not
performed for 10X during this initial testing, however it was performed at a later date and found to be
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0.67BF/mm. The radiation-collimator isocentricity in the GT direction of all energies were calibrated
within 0.10mm.

Bending Fine vs. GT Radiation
Beam Center

Bending Fine

4
3.5
3

6X
6FFF
10FFF
15X

2.5
2
1.5

0.6

0.8

1

1.2

1.4

1.6

BB-Beam Center GT Deviation (mm)

Figure 11: Iterative adjustment of bending fine to achieve the ideal BB-beam center GT deviation
(0.87mm). The 10X energy did not require adjustment.
The post beam-adjustment 3-dimensional linac isocenter locations, as determined by the 8-field
WL tests, are shown in Table 1. The maximum Euclidian distance between any two isocenters was 0.20mm
(6FFF and 15X). The largest spread in the GT direction was 0.10mm, which matches the 0.10mm deviation
that was measured during the aforementioned calibration.
Versa HD Multi-Energy Isocentricity
Linac
Couch
Overall
AB
GT
UD
Table X
Table Y
Radius
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
6X
0.04
0.00
0.08
0.15
-0.08
0.8
10X
0.02
-0.06
-0.01
0.1
0.12
0.88
15X
0.02
-0.01
-0.11
0.04
0.20
0.91
6FFF
-0.06
0.04
0.07
-0.15
-0.08
0.98
10FFF
-0.03
0.01
-0.01
-0.18
-0.06
0.87
Average
0.00
0.00
0.00
-0.01
0.02
0.89
Table 1: WL results showing the linac isocenter coincidence across all energies, coincidence between the
couch rotation axis and linac isocenter, and overall radiation-imaging coincidence for all gantry,
collimator, and couch angles.
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The post table-adjustment coincidence between the couch rotation axis and the linac isocenter
position for each photon energy is shown in Table 1. The overall radiation-imaging isocentricity for all
gantry, collimator, and couch angles of all energies was less than 1.0mm.
Discussion
Following this procedure, the beam centers were matched to within 0.10mm in the GT direction.
A similar procedure can be repeated to match the energy isocenters in the AB (left-right) direction.
However, there is no easily adjustable parameter, like bending magnet current, which can steer the beam
in the AB direction. Rather, if a discrepancy is found, the symmetry should be checked, followed by an
examination of the beam startup.
Many of these measurements can be performed using the stored beam option in the Versa HD
service mode. However, caution should be used when switching between energies in stored beams as
there can be a hysteresis effect where the previously selected energy effects the current measurement.
In the context of this procedure, this is particularly problematic when switching from a higher energy to a
lower energy. Instead of starting from a low bending magnet current (bending magnet coarse parameter
in service mode) and increasing the current to the appropriate value for the beam energy, as is done in
clinical mode, the linac will drop the bending magnet current when switching from a higher energy to a
lower energy in stored beams. Approaching the desired bending magnet current from a different
direction can cause the beam center to shift. To prevent this issue, it is recommended to first load a field
of the desired energy using the quick beam service page, prior to switching energies in the stored beams
service page, particularly when switching from high to low energies. Loading a field of the desired energy
in the quick beams service page, will mimic the bending magnet behavior of clinical mode and prevent
the hysteresis behavior when switching back to stored beams.
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The ideal location for the cross-energy isocenter calibrations was determined by correlating the
results of the HBB test with the BB-beam center deviations for all energies. However, the main reason for
performing the HBB measurements is to correlate the results with the BB-beam center deviations to find
the GT deviation in the images that corresponds to the collimator rotation axis. The collimator rotation
axis is a mechanical property of the machine that should not change between energies. From Figure 9,
the maximum difference in ideal BB deviation, corresponding to the collimator rotation axis, between
energies was 0.008mm. Therefore, to reduce calibration time, the HBB and BB-beam center deviation
measurements can be performed for a subset of energies.
Various vendors manufacture BB jigs that attach to the couch and allow micrometer adjustments
of the BB position in a specified direction. In practice, shifting the BB along one direction often leads to
unwanted small changes in orthogonal directions. For example, moving the BB in the GT direction may
inadvertently cause a shift in the AB direction. Alternatively, the 6 degree of freedom Hexapod couch can
be used to move the BB. It was found that the Hexapod couch can reproducibly move a BB within 0.10mm
of isocenter in all directions. Regardless of the movement method, care should be taken to level the couch
and align it as close to angle 0 degrees as possible to ensure translational couch movements correlate
with the gantry coordinate system.
For the Versa HD tested in this study, it was possible to achieve <1mm radiation-imaging
coincidence for all energies. In practice, SRS/SBRT tolerances may only be maintained for selected
energies on the treatment machine. Table 2 shows two tolerance levels for the individual steps of the
described procedure. It is recommended that Tolerance A values be met for all energies that will be used
for SRS/SBRT. Tolerance B values, which were achieved during commissioning, are the limits at which it
is expected that any additional work may result in diminishing returns.
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Versa HD Isocentricity Tolerances
Tolerance A
Tolerance B
Beam center vs. collimator rotation axis coincidence
0.20mm
0.10mm
Cross-energy linac isocenter coincidence
0.50mm
0.20mm
Linac isocenter vs. couch rotation axis coincidence
0.50mm
0.25mm
Table 2: Tolerance A: Easily achievable on all Versa HDs. Tolerance B: lower expected limit of what is
achievable.
Furthermore, the shape and magnitude of inherent couch-wobble will vary between Hexapod
couches. This may affect the achievable imaging-couch isocenter coincidence for a given linac. If an
inherent couch wobble is large enough to prevent the calibration of all energies within the 1.0mm
SBRT/SRS tolerances, it is recommended that a subset of the energies be calibrated for SRS/SBRT or the
couch be replaced.
Conclusion
A procedure was developed to calibrate the cross-energy radiation isocenter locations for all
photon energies on multi-energy linac. It was implemented during commissioning of a Versa HD, where it
was able to achieve the radiation-imaging coincidence tolerance of <1.0mm for all energies. This work
provides a framework to help physicists achieve SRS/SBRT tolerances in a simple and precise manner,
eliminating much of the tediousness usually encountered when optimizing machine isocentricity.
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CHAPTER 3 AN ANALYSIS OF CONFIDENCE LIMITS USED IN AAPM TASK GROUP NO. 119
Using a set of standardized phantoms and measurement protocols, AAPM Task Group #119
established quantitative confidence limits as baseline values for the purpose of evaluating IMRT
commissioning96. For all criteria presented in the report, confidence limits (CL) are determined under the
assumption of a random distribution of measured values, thereby establishing these limits as a function
of the standard deviation of a normal distribution. As noted in the report, assuming the measured data
to fall along a normal distribution may not be valid for IMRT gamma index pass rate data.
During IMRT quality assurance, planar dose distributions are measured using detector arrays, film
or electronic portal imaging devices (EPIDs)

130-132

. The measurements are compared to planar dose

distributions using a gamma evaluation introduced by Low et al.133. The goal of the evaluation is to
determine if the treatment machine can accurately deliver the calculated dose from the planning
software. The gamma index analysis is performed for multiple points in the plane and the percentage of
points which pass the analysis are reported as the gamma index pass rate. The gamma index pass rate has
lower and upper bounds of 0% and 100% respectively. These bounds — the 100% upper bound in
particular — prevent the measured data from following a true normal distribution. Quantitative CLs
established in the report for gamma pass rate based on unbounded normally distributed data are,
therefore, approximations of the CLs defined on the true bounded distribution of the data, and may not
accurately reflect the statistical confidence sought through their use.
In order to evaluate CLs more representative of the TG #119 gamma pass rate data, an accurate
fit of the data must first be found. Since the gamma pass rate data is bounded at 100%, an asymmetric
distribution should be employed. In this study we chose two asymmetric distributions to attempt to
better represent the data: a truncated normal distribution and a Weibull distribution. Using these
distributions we can fit the data by employing Maximum Likelihood Estimators (MLE), and from there
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determine confidence intervals on IMRT data sets. In addition to comparing the CLs of different
distributed fits on IMRT data, we also attempt to make more general statements about the differences
between the CLs established in this situation by a standard normal distribution and the asymmetric
distributions described above.
If the CLs determined by fitting the measured data to more accurate distributions significantly
differ from those in determined in TG #119, then, at the very least, the interpretation of the approximated
CLs needs to be amended. Furthermore, if the difference between the TG #119 CLs and those calculated
using stricter fits of the data changes significantly as the measured data changes, not only must the TG
#119 CLs be interpreted differently, but the utility of the approximation presented in the TG report could
be compromised.
In this work we investigate methods for calculating CLs with truncated normal and Weibull
distributions, and compare those limits with CLs calculated using the TG #119 formalism. We then discuss
the potential impact of this truncated modeling on the IMRT commissioning criteria presented in TG #119.
Material and Methods
In order to test the differences between CLs determined in the method of TG #119 and those
determined by tighter fits of the data, we analyzed clinical gamma pass rate data using TG #119’s normal
distribution and two truncated asymmetric distributions: truncated normal and Weibull. Our data
consisted of gamma pass rate values for 111 Head and Neck patients from the Karmanos Cancer Center
(Detroit, MI). The data was collected using Mapcheck (Sun Nuclear Corporation) and analyzed with a
3%/3mm gamma index using a cutoff criteria of 10% of the maximum dose.
In Figure 12, we present a frequency plot of the 111 gamma index pass rates using a bin size of
0.5%. The figure also displays fits to this data using the TG #119 method (normal distribution), a truncated
normal distribution, and a Weibull distribution. To determine how well the fits describe the data, we used
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the Kolmogorov-Smirnov (K-S) goodness-of-fit test. CLs were determined for each of these cases as
described below.

Figure 12: Gamma Index pass rates for 111 Head and Neck IMRT QAs. Three distributions were fitted to
the data (normal, truncated normal, and Weibull). Maximum Likelihood Estimators were used to obtain
the optimal fitting parameters of the distributions.

Truncated Asymmetric Distributions
To describe the first asymmetric distribution we choose to employ, it is helpful to begin with a
description of the standard normal distribution used in TG #119 to approximate gamma index pass rate
data. The normal distribution is characterized by two constants, the mean, µ, and standard deviation, σ,
where µ represents the most probable outcome and σ is a measure of the spread of the measurements
from the mean (Equation 3).
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For a truncated normal distribution, only the range within which the distribution is defined as
non-zero changes. As opposed to the standard normal distribution defined over all space, the truncated
normal distribution is defined only within a specified range, which, for our purposes, is 0 <x<100. The
parameters µ and σ no longer represent the mean and the standard deviation of the distribution, but
instead are simply parameters describing the distributions’ shape134. The actual mean and standard
deviation of the distribution must be calculated on the non-zero interval defined above. The parameters
µ and σ can still be thought of as the mean and standard deviation of the un-truncated normal distribution
from which the truncated distribution was established. This remains helpful for visualization, as the
parameter µ represents the peak of the distribution when it falls within the non-zero range.
The other distribution fitted to the TG #119 data is the Weibull distribution given by:

(x− )k , x ≥ 0

k  x −  k −1 − 
P
( x) = 
e

Weibull
  

(4)

where k, λ and θ are the shape, scale and shift parameters respectively135. Depending on the parameters,
the Weibull distribution can resemble a normal, Poisson or exponential distribution. The shape parameter,
k > 0, is the primary variable which affects the distribution that the Weibull will most closely resemble,
while the scale parameter, λ > 0, primarily controls the structure of the chosen distribution. The final
parameter θ, allows the distribution to shift along the x-axis much like the normal distribution parameter
µ shifts the mean of the normal distribution. The Weibull distribution is defined only for x ≥ 0, and thus is
naturally truncated. To employ this natural truncation of the Weibull, we reflect our data and reinterpret
it as a set of gamma index failure rates. The resulting failure rate data is truncated at zero and has a mean
very near the truncation point — an ideal data-set to model with a Weibull distribution.
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Maximum Likelihood Estimators
Modeling gamma index pass rate data using the asymmetric distributions described above
involves fitting the data using an MLE method. The MLE method involves calculating a maximum likelihood
function, H, with a wide range of model parameters. The optimal model parameters, and therefore the
optimal distribution fit, are then chosen as those that maximize H. For the example of a truncated normal
distribution, the maximum likelihood function derived by Cohen134, 136is:

H ( x0 , x1 , x n ;  ,  ) = [1 − F ( )] ( 2 )
−n

−n

 n
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where xn is the measured data, σ affects the shape of the distribution and µ still represents the most
probable measurement of the distribution.
For a sample that is truncated on the right, such as the gamma index, F(  ) is the probability that
a measured value will be truncated by the upper limit (L).
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The computer MLE calculation is performed by varying µ and σ to find the values which maximize H(x;µ,σ).
Example MLE calculations that are written in Matlab and Mathematica have been described by Myung137
and Currie138 respectively.
For distributions other than a truncated normal distribution, such as the Weibull distribution, the
same type of analysis is possible139. The functions H and F are defined for the given distribution, and H is
maximized to determine the set of parameters that give the best fit to the measured data.
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Confidence Limit Calculations
TG #119 approximated their gamma index pass rate data with the normal probability distribution
(Eq. 3). The CL of the normal distribution is traditionally described as a range around the mean of the
data(±w) and determines the probability that a single measurement will fall within that range. It is usually
calculated such that 95% of the measured points are expected to fall within that range (Figure 13).
Integrating the normal distribution gives this confidence interval to be CL = mean ± 1.96σ (Eq. 7).
 +w

0.95 

 P( x)dx , where CL (µ-w,µ+w)

(7)

 −w

Following the methods of Venselaar140 and Palta141, TG 119 used this equation to calculate the CL.

Figure 13: Comparing the 95% confidence limits (CLs) for a normal and a truncated normal probability
distribution. The normal CL is defined around the mean of the distribution. The truncated normal CL is
defined by the truncation point and a lower bound.
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When using a truncated asymmetric probability distribution (T(x)), a portion of the domain on
which the original, un-truncated probability function is defined is not included. Therefore, the probability
function is re-normalize to exclude these values. This re-normalization is shown in Equation 8 for the
gamma index pass rate, with limits of 0 and 100%.

T ( x)
Tnormalized ( x) = 100
 T ( x)dx

(8)

0

When analyzing IMRT gamma index pass rates, we want to determine the CL such that 95% of our
measurements are larger than a specified gamma index (Lo), as opposed to a range around a mean value.
The two different CLs are shown in Figure 13. Equation 9 was used to calculate the CLs for the gamma
index pass rates.
100

0.95   Tnormalized ( x)dx , where CL  (Lo,100)

(9)

Lo

As a general method to establish confidence limits in a truncated dataset such as IMRT gamma
pass-rate data, we employ a three-step process: we first model the data with a truncated asymmetric
distribution using the MLE method (Equation 5), we then renormalize the data on the truncated interval
(Equation 8), and finally, we calculate a CL by integrating the renormalized probability distribution
(Equation 9).
Modeling Expected Differences in CL
To provide a more generalized understanding of possible differences in CLs calculated using the
different methods, we tested the accuracy of the TG #119 CL calculations in a multitude of idealized
situations. For a range of parameters (e.g., µ and σ for a truncated normal distribution) an asymmetric,
truncated probability distribution was calculated, and the resulting distribution was assumed to represent
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an ideal set of IMRT gamma index pass rate data. CLs for the simulated gamma pass-rate data were then
found using both the truncated CL definition (Equation 9) and the TG #119 definition (CL = mean ± 1.96σ).
We then calculated the difference between the TG #119 and truncated CLs. The analysis was performed
for both the truncated normal distribution, and the Weibull distribution. Due to the fact that the Weibull
distribution has three parameters to vary (λ, k, θ), we performed the above analysis for only a few values
of the shift parameter, θ.
Results
The results of the analysis of our H&N pass rates are presented in Table 3 and Figure 14 and Figure
15. The differences between the CLs calculated with TG #119 and our asymmetric distributions were
0.09% and -0.03% for truncated normal and Weibull distributions respectively. The K-S statistics were
calculated using the K-S test and the P-values were estimated from published tables142, 143.
Untruncated Normal
MLE Fitted

Truncated Normal

Weibull

µ

98.67

µ

99.2

k

1.63

σ

0.90

σ

1.23

λ

1.59

θ

-0.10

Parameters
95% Confidence Limits

96.91%

97.00%

96.99%

K-S Statistic

0.1417

0.1065

0.0856

K-S P-value

<0.01

~0.01

~0.05

Table 3: Three distributions were fitted to gamma index pass rate data for 111 Head and Neck IMRT QAs.
Confidence limits were calculated for each distribution and Kolmogorov-Smirnov goodness-of-fit tests
were performed.
Figure 14 and Figure 15 are the expected differences for the CLs that were calculated using the
procedure described previously where a series of ideal pass-rate data was simulated with both truncated
distribution types. Figure 14 shows the differences in CLs when the data was simulated with a truncated
normal. In Figure 14 the largest differences between the calculated CLs is approximately 1.2%. As the
mean of the distribution gets further away from the upper bound (100%), the difference in the CLs will
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continue to slightly increase. However, Palta et al.141 and TG #119 suggest a clinical action level of 90%,
therefore lower mean pass rates have been omitted from the analysis.

Figure 14: The difference in confidence limits that were calculated using the Task Group # 119 method
and the truncated normal method. The axis values are the µ and σ parameters, which describe the
truncated normal distribution.

Figure 15 shows the differences in CLs when the data was simulated with a Weibull distribution.
The largest difference between the calculated CLs was approximately 1.0%. The data in Figure 15 was
calculated with a constant shift parameter equal to zero. Changing the shift parameter of the Weibull
distribution does affect the calculated difference for each (λ,k) pair, however the maximum difference, as
shown in Figure 15, was independent of the value of the shift parameter.
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Figure 15: The difference in confidence limits that were calculated using the Task Group # 119 method
and the Weibull method. The axis values are λ and k parameters, which describe the Weibull distribution.
The shift parameter (θ) is set to zero.

Discussion
Somewhat surprisingly, the CLs determined for each distribution type on both measured data,
and on simulated idealized data differ very little. Despite the poor fit that a normal distribution gives to
a truncated data-set, specifically designed to not be normally distributed, the resulting CL found using the
TG #119 definition differs at most by approximately 1.2%. Moreover, the maximum CL differences are
found only at parameter values where the idealized data are near the clinically acceptable limits96, 141. The
apparent unimportance of accurate distribution fit likely arises from two competing factors: the differing
definitions of CL between the fitting methods, and the better fit to the data itself. The way in which CLs
are calculated here for the asymmetric distributions immediately shifts the CL closer to 100%, as we have
taken the definition to be representative of the point above which 95% of the data most probably lies, as
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opposed to TG #119 which takes the definition of CL to be lower point defining the range inside of which
95% most probably lies. In competition to that shift, however, is a shift away from 100% due to the overall
ability of the distribution to more accurately fit the data, which tends to flatten out the asymmetric
distribution in comparison to a standard normal fit.
The K-S goodness-of-fit test showed a higher probability that our limited data set originated from
Weibull distributed data than for either the normal distribution or the truncated normal. Despite the
better fit of the Weibull relative to the other distributions, the low p-value of the MLE determined Weibull
shows that it is far from a certainty that the distribution of IMRT gamma index pass rates can always be
described in this way. Nevertheless, the 5% probability associated with the Weibull fit significantly
improves upon the very low probability for a normally distributed data set, and in fact, as data were added
to the statistics during the completion of this study, the trend of the data set was consistently towards a
higher probability of Weibull fit.
The better fits shown in Figure 12 may advocate the use of the MLE method in all fitting scenarios,
but there are drawbacks to the MLEs. The MLE method is a cumbersome process that involves writing
programming code to determine the optimal solution. A possible solution, if indeed even necessary, would
be to create a distributable MLE program that could accompany TG #119. Even with a compact MLE
program, there is a biasing effect when using MLEs to fit small data sets to Weibull distributions144, 145. The
biasing effect can lead to differences in the calculated CLs. The effect can be calculated, however this
would further increase the complexity of the MLE method.
The confidence limit calculations used to generate Figure 14 and Figure 15 were performed with
an ideal data set. This was done as a theoretical example to show the differences in CL calculations that
we would expect when using the two different methods. In real IMRT measurements, the fitted
distribution will not perfectly describe the data. Rather, the fitted distribution is a best guess of the true
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probability distribution, based off of a limited data set. Therefore the difference in the CL calculations may
be different from our simulated situation. Furthermore, the simulation was performed by assuming that
gamma index pass rate data follows either a truncated Gaussian or a Weibull distribution. In reality, the
statistical distribution of the pass rate data is probably more complex. However, as the goodness-of-fit
tests show, the three-parameter Weibull distribution has the ability to approximate clinical gamma index
pass rate data.
Conclusion
A straight normal fit to measured gamma pass rate data is almost always going to be a very poor
approximation of the distribution due to the upper bound of 100% on the gamma pass rates. However,
due to the small range of distributed data points, a confidence limit determined by assuming a straight
Gaussian fit will likely be within 1.2% of those determined by other, more accurate fits of the data. Given
the scarcity of data points in the IMRT commissioning process, the approximation introduced in TG #119
allows for a significant simplification of data analysis while being accurate to within the limitations of the
data set itself.
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CHAPTER 4 IMRT QA MEASUREMENTS – PTW’s 1000 SRS
Introduction
IMRT quality assurance (QA) consists of delivering patient plans to dosimetric measuring devices
and comparing the dose to that predicted by the treatment planning system (TPS). The devices must
accurately measure dose with high enough resolution to sufficiently characterize the field. When small
field sizes are used this requires the close placement of small detectors146, 147. This can cause issues when
using air filled ionization chambers, typically used in non-IMRT radiation dose measurements110, 148. The
low-density air results in less scatter and a low signal to noise ratio, which limits the proximity and size of
the detectors.
One potential solution is to use liquid-filled ionization chambers (LICs), which use higher-density
liquid to increase response and scatter149, 150. However, there is a tradeoff – the liquid reduces ion mobility,
leading to ion collection times that are approximately 100 times larger than air-filled chambers, which
increases ion recombination effects151-157. Ion recombination effects have been studied in LICs and found
to be proportional to the frequency and dose of the pulses delivered to the detector, among other things.
The dose and frequency of the pulses at each detector will vary during an IMRT delivery due to the
changing MLC aperture and changing machine MU/min, respectively. This could potentially introduce ion
recombination effects into QA measurements, resulting in a distortion of the dose map and overall IMRT
QA results.
The PTW 1000 SRS array (PTW, Freiburg, Germany) implements the above described LICs, for
small field IMRT measurements158.

The goal of this research is to determine the effect of ion

recombination on clinical 1000 SRS IMRT QA measurements and investigate two potential ion
recombination correction methods.
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Materials and Methods
The device used in this study is the 1000 SRS detector. The 1000 SRS detector consists of 977
isooctane-filled liquid ionization chambers (LICs). The chambers have dimensions 2.3mm x 2.3mm x
0.5mm (depth). The chambers are arranged in a planar array with a spacing of 2.5mm in the center of the
array and 5.0mm at the periphery (Figure 16). During measurements the array was placed in a rotating
Octavius 4D phantom, which uses an inclinometer to keep the array aligned perpendicular to the axis of
the beam159. All measurements were performed on a TrueBeam linear accelerator (Varian Medical
Systems, Pal Alto, CA) equipped with a high definition multi-leaf collimator (HD-MLC).

Figure 16: 1000 SRS detector locations. Detectors are 2.3mm wide squares. Centroid spacing is 2.5mm in
the center and 5.0mm in the peripheral.
LIC ion recombination
The evaluation of the 1000 SRS detector began by determining the correlation between collection
efficiency and pulse dose for the 1000 SRS LICs in 6MV and 10FFF beams. This investigation consisted of
exposing the 1000 SRS detector to different pulse dose rates, measuring the dose, and comparing the
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results to true dose measured with a 0.125cm2 model 31010 air-filled ionization chamber (PTW, Freiburg,
Germany) to determine the LIC collection efficiencies.
To create a consistent setup where the 1000 SRS detector measured the same pulse dose as the
ion chamber, the detectors were alternately placed at the same location in a virtual water stack. Prior to
measurements, both devices were by pre-irradiated, per manufacturer recommendations. After preirradiation, 9.1cm of solid water was placed on top of the 1000 SRS – combined with the 0.9cm buildup in
the device this resulted in an equivalent depth of 10cm. The distance to the surface of the solid water, or
source-to-phantom distance (SPD), was set to 100cm. 100Mus were delivered to the 1000 SRS using a
10cm x 10cm field with the maximum dose rate of 600MU/min and 2400MU/min for 6MV and 10FFF,
respectively. For subsequent measurements, the SPD and buildup on top of the 1000 SRS was varied to
produce different pulse doses at the detectors.

For each SPD and depth combination, the 1000 SRS

measurements were divided by the ion chamber reading, which was corrected for Ptp, Ppol, and Pion using
TG51 formalisms108. These ratios were subsequently normalized to the dose/charge ratio at 100cm SPD
and 10cm depth. The change in the dose/charge ratio at each SPD/depth combination was attributed to
the different collection efficiencies of the LICs caused by the different pulse doses.
To correlate the LIC collection efficiencies with pulse dose, the pulse dose at the 1000 SRS central
chamber was calculated for each SPD. The dose and number of pulses were determined separately and
then used to calculated pulse dose. First, dose was obtained for 100cm SPD by simulating the delivery in
the Eclipse TPS (Varian Medical Systems, Pal Alto, CA), and calculating dose to the center detector. To
eliminate any potential dosimetric effects caused by calculating dose in the treatment planning system at
different SPDs, the ratio of the corrected ionization chamber readings were used to convert dose at 100cm
to dose at other SPDs.
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The number of pulses was determined from the pulse repetition frequency of the linac and the
delivery time. The deliveries were performed at the maximum MU/min (600MU/min and 2400MU/min
for 6X and 10FFF, respectively), which corresponds to a linac pulse frequency of 360Hz. Pulse frequency
and calculated dose to the 1000 SRS detector were used to calculate pulse dose at each SPD.
The collection efficiencies were plotted against the pulse dose for different SPDs to obtain the
pulse dose dependency of the 1000 SRS detector central chamber. The plotted data was modeled using a
linear least-square fitting method. Based on the fitting results, a constant was subtracted from all of the
collection efficiency data so that the modelled collection efficiency was 1.0 for a 0.0mGy/pulse rate.
To study the effect of pulse frequency on collection efficiency, the above procedure was repeated
with different MU/min. The set MU/min were used to calculate pulse frequency using the linear
correlation between the two parameters and the fact that the max MU/min corresponded to a 360Hz
pulse frequency.
IMRT ion recombination corrections
The following is a brief description of how the 1000 SRS is used in the Octavius 4D system for
clinical IMRT QA measurements. 1000 SRS measurements are performed in the Octavius 4D system, which
consists of a rotating phantom that keeps the array perpendicular to the beam using an inclinometer
attached to the gantry. Prior to a QA measurement, the central chamber of the 1000 SRS is calibrated to
a known dose using a reference beam from the linac. A default Co-60 array calibration file, included with
the device, has chamber-specific calibration factors, which are scaled using the daily central chamber
calibration, thereby calibrating the whole array. Once calibrated, treatment fields are delivered to the
1000 SRS, which measures dose in user defined collection intervals (0.2s for this study) as a function of
gantry angle. For each collection interval, a vendor-supplied analysis software (VeriSoft) takes the
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measured dose and uses PDDs to back-project a 3D dose throughout the phantom. The total dose, from
all collection intervals, is combined and compared to the TPS using a 3D gamma analysis56, 160.
The daily 1000 SRS calibration is performed at a standard pulse frequency and pulse dose. During
a 1000 SRS measurement, the changing MU/min and MLC aperture will cause the pulse frequency and
dose to vary across the detector, which will cause changes in the collection efficiency. The changing
collection efficiency could potentially cause errors in the IMRT QA measurement. To determine the
magnitude of this effect the collection efficiency determined in the previous sections were used to correct
clinical 1000 SRS measurements. The details of the IMRT measurements, the corrections, and the IMRT
analysis are presented in the subsequent sections.
IMRT Measurements
The effects of ion recombination were studied in seven clinical SBRT plans: four lung, two spine,
and one liver plan. The number of available clinical lung SBRT cases far outweighed spine and liver cases,
however a variety of plans were chosen to provide a broad case-set for studying ion recombination
effects. All plans used RapidArc deliveries. All of the plans were re-planned on the same machine
(TrueBeam) for both 6MV and 10FFF energies, using the original clinical dose objectives specified by the
physician and a 1.5mm calculation voxel size, per department protocol. Each plan consisted of 4 or 6 arcs.
In total, 34 arcs were measured for each energy. Each arc was delivered individually to the Octavius 4D.
The measured dose was compared to the dose calculated in the TPS using a 3D gamma analysis. In this
work the 3D gamma analysis was performed with a 3%/3mm, 2%/2mm, and 1%/1mm global criteria using
a threshold that excluded measurements below 10% of the maximum calculated TPS dose. Finally, the
measurements were corrected for ion recombination effects using the procedures in the following
sections, and then re-analyzed.
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Measurement Corrections
Ion recombination effects in 1000 SRS measurements are caused by the difference in collection
efficiencies between the daily array calibration and the IMRT delivery. To correct this effect in the 1000
SRS measurements, the pulse frequencies and pulse dose for both calibration and the IMRT measurement
were calculated. The pulse information was used to find collection efficiencies using the measured
relationships from the previous section. Finally, the ratio of calibration/measured collection efficiencies
were used as correction factors for the 1000 SRS measurements.
First, the pulse dose during 1000 SRS calibration was calculated. The dose to the central chamber
was calculated from the TPS. The number of pulses was calculated from the MU/min of the machine and
the delivery time (360Hz when using the maximum MU/min).
Pulse frequency and dose during a measurement were calculated using the 1000 SRS
measurement file and data from the TPS. The formula for determining the pulse dose during a
measurement is shown in Equation 10. This formula assumes a constant pulse dose throughout the
individual collection intervals of the Octavius 4D, which was set to 0.2 second for all of the measurements.
This limitation in temporal resolution, makes it difficult if not impossible to distinguish separate pulses only the average pulse frequency during the collection interval is obtainable. As such, Equation 10 does
not calculate the actual pulse dose, rather it will calculate the average pulse dose during the 0.2 second
collection interval.
Furthermore, the dose rate servo of the TrueBeam may modulate the pulse structures (height and
width) to modulate dose rate. This correction technique assumes a change in collection efficiency due to
increasing pulse frequency with increasing dose rate; however, the decrease in collection efficiency due
to frequency increase may not match the decrease in collection efficiency due to a change in pulse
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structure. This is an inherent limitation in this correction technique, which warrants the additional
investigation of a simpler correction method.
Dosemeasured is the amount of dose measured by each chamber during a single sampling time.
MU/minmeasured is the MU/min of the machine during the sampling interval. MU/minmax is the maximum
MU/min of the machine for each energy: 600MU/min for 6MV and 2400MU/min for 10FFF.

Dose
Dosemeasured
MU / min max
1
=
*
*
Pulse MU / min measured 360 pulses / sec collection time

(10)

The Dosemeasured was taken directly from the Octavius 4D measurement files.
The MU/minmeasured was found using information from the measurement file and the TPS. The TPS
stores a table containing MU/min as a function of gantry angle. For each plan, the MU/min vs. gantry
angle table was exported from the TPS into the Matlab software. The Octavius 4D system records the
gantry angle for each measurement point, which was used to lookup the MU/minmeasured from the TPS
table. Planned MU/min was used instead of the delivered MU/min due to the uncertainty in the Octavius
4D inclinometer reading that resulted in unrealistic pulse doses when measurements were matched with
the delivered MU/min from the beam trajectory files. Using the planned MU/min resulted in more realistic
pulse doses, especially when there were large changes in MU/min as a function of gantry angle.
Using the data from the previous paragraphs and Equation 10, the pulse frequency and dose at
every detector was found for each measurement point. The pulse information was used to calculate
collection efficiencies via the measured relationships from the previous sections. Due to the low
resolution of the collection efficiency vs. frequency data (Figure 18), linear interpolation was used to
calculate collection efficiencies for frequencies that were not multiples of 60Hz (MU/min not multiples of
100MU/min and 400MU/min for 6X and 10FFF, respectively). The collection efficiencies were used to
determine correction factors for each measurement point. Correction factors, shown in Equation 11, were
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the ratios of the collection efficiency at the time of daily calibration (CCE), divided by the collection
efficiency during the measurement (MCE).

Correction Factor =

CCE
MCE

(11)

Each measurement point was subsequently multiplied by its corresponding correction factor.
This correction method provides corrections for changes in both pulse frequency in dose.
However, the correction method is cumbersome and may not easily implemented in standard QA
practices. Therefore a second correction was tested that involved simply matching the 1000 SRS daily
calibration MU/min to the expected average MU/min of the plan. For simplicity the daily calibration
correction will be referred to as the “simple” correction, while the Matlab correction will be referred to
as the “complex” correction.
The simple correction only accounts for changes in pulse frequency and as such was expected to
be less accurate than the complex correction for changes in pulse frequency and dose. To determine the
accuracy of the simple corrections, the resulting QA pass rates were compared for both correction
techniques.
One issue with the simple correction method is that the TrueBeam linear accelerator only allows
the selection of discrete MU/min values during 1000 SRS calibration, making it impossible to exactly match
the calibration MU/min to that of the plan. Therefore, a clinical user may have to choose a calibration
MU/min that is higher or lower than the plan. To determine whether this choice has a major effect on QA
results, the effect of both high and low MU/min corrections were tested and the resulting QA pass rates
were compared.
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IMRT analysis
After applying the correction factors to the measurements, the Octavius 4D measurements were
analyzed in the VeriSoft software package. VeriSoft uses PDDs to project the measured dose from the
1000 SRS throughout the phantom. Dose from each projection is summed, and compared to the dose
predicted by the TPS using a 3D gamma analysis. In this work a 3%/3mm, 2%/2mm, and 1%/1mm global
criteria were used with a 10% threshold. In total 7 patients were analyzed, with two plans per patient (6X
and 10FFF), for a total of 34 arcs per energy. For each arc, an analysis was performed with and without
pulse dose corrections and the differences in gamma pass rates were calculated.
To correlate the change in gamma pass rates with plan parameters, the average MU/min and
average MLC aperture size were calculated for each arc. DICOM RT plan files were imported into Matlab,
where the MLC positions and meterset weights were used to calculate the average aperture size for each
arc. Planned MU/min and meterset weights taken from the DICOM files were used to calculate average
MU/min. The per-arc parameters were compared to the average change in 1%/1mm gamma pass rate for
each plan using a linear regression analysis, and Pearson correlation coefficients were calculated.
Results
Figure 17 shows the collection efficiency of the 1000 SRS LICs for 6MV and 10FFF, averaged over
four days. The results are presented without error bars for clarity, however the uncertainty of the
measurements are included in the slope uncertainties shown in Figure 18. The collection efficiencies were
linearly correlated with pulse dose. As expected, collection efficiencies increased as both pulse dose and
pulse frequency decreased. The change in collection efficiencies as a function of pulse dose were slightly
larger for 10FFF, changing by 5.01%/(mGy/pulse) at 360Hz (2400MU/min), compared to
4.44%/(mGy/pulse) for 6X, when a 360Hz (600MU/min) pulse frequency was used.
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(a)

(b)

Figure 17: 1000 SRS liquid filled ionization chamber collection efficiencies as a function of pulse dose and
pulse frequencies delivered to the detector for (a) 6MV and (b) 10FFF.

The magnitude of the slopes from the collection efficiency versus pulse dose regression analysis
are plotted against pulse frequency in Figure 18. Error bars in Figure 18 are the calculated standard
deviations of slope measurements that were repeated over multiple days. This data was used in the ion
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recombination corrections to find the change in collection efficiencies for measurements with different
combinations of pulse dose and pulse frequency.

1000 SRS Collection Efficiency
for various pulse frequencies
0.06
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Figure 18: Magnitude of ion recombination effects as a function of pulse frequency. All measurements are
for multiples of 60Hz (100MU/min for 6X and 400MU/min for 10FFF) – they have been offset for improved
visualization. The vertical axis is the percent change in ion collection efficiency for a given change in pulse
dose.

IMRT analysis
The change in 3D gamma pass rates from the ion recombination corrections are shown in Table I
for 6MV and 10FFF. For all fields, pass rates improved after corrections. For each plan, the changes in
pass rates were averaged over all arcs. The per-plan change in pass rates, found by averaging the pass
rate changes for all arcs in a single plan, were used to calculate average (Avg.), maximum (Max.), and
standard deviation ().
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3D Gamma Pass Rate Changes
3%/3mm
2%/2mm
1%/1mm
Energy
Avg.
Max.
Avg.
Max.
Avg.
Max.
6X
0.07
0.16
0.43
0.40
0.66
1.63
1.17
1.14
3.05
10FFF
0.29
0.40
1.00
1.40
2.09
4.80
4.57
3.71
11.20
Table 4: Changes in gamma pass rates from complex ion recombination corrections. The average (Avg.),
standard deviation (), and maximum (Max.) changes were calculated from the per-plan changes in pass
rates.
Simple corrections produced pass rates both larger and smaller than complex corrections. To
quantity the difference in pass rates between the two correction methods, the absolute difference in perarc pass rates were calculated and the results are shown in Table 5. During simple corrections the nearest
possible calibration MU/min was selected to match the plan. Both the results for rounding up (High) and
rounding down (Low) to the nearest MU/min are displayed. On average the direction of rounding had less
than a 0.5% effect on pass rates. However, selection of the lower calibration MU/min produced pass rates
closer to the complex corrections.
Pass Rate Difference Between Correction Methods

Energy
6X
10FFF

MU/min
High
Low
High
Low

Avg.
0.03
0.01
0.01
0.00

3%/3mm

0.05
0.02
0.02
0.01

Max.
0.1
0.0
0.0
0.0

Avg.
0.21
0.10
0.27
0.18

2%/2mm

0.19
0.06
0.16
0.08

Max.
0.5
0.2
0.5
0.3

Avg.
0.78
0.43
0.98
0.80

1%/1mm

0.30
0.28
0.58
0.42

Max.
1.2
0.7
2.2
1.7

Table 5: Comparison of the 3D gamma pass rate results obtained after simple and complex ion
recombination corrections. The average (Avg.), standard deviation (), and maximum (Max.) changes
were calculated from the absolute values of per-arc changes in pass rates.
Figure 19 shows dose profiles displaying the effects of ion recombination corrections for a single
arc. The dose profile is taken along the C/A of the detector. The profiles are truncated below 10% of the
maximum dose, to show the measurements that will be included in the gamma analysis. The uncorrected
(measured) and corrected dose planes are compared to the dose predicted by the treatment planning
system(TPS). The difference between measured and corrected dose has been plotted as an absolute
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difference (M-C) and a relative difference ((M-C)/M*100%). The relative distance represents the
magnitude of the ion recombination corrections at those detector locations.

(a)

Figure 19: Dosimetric effects of complex ion recombination corrections. (a) Measured and ion
recombination corrected dose profiles along the central axis of the 1000 SRS compared to the TPS
predicted dose. (b) Difference between measured and corrected profiles. The relative distance is plotted
on the right vertical axis.
Figure 20 shows the average per-plan change in pass rates due to recombination corrections
plotted against average planned MLC aperture size and average MU/min. The equations from the linear
regression are shown on the plots along with the Pearson correlation coefficients. Changes in pass rates
were weakly correlated to average MLC aperture size, however they tended to increase as smaller
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aperture sizes were used. Changes in pass rates were more strongly correlated to MU/min, increasing as
average MU/min decreased.

Dose-per-pulse Corrections vs Aperture Size
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Figure 20: Correlation between changes in 3D gamma analysis pass rates (ΔPR) from pulse dose
corrections and (a) average MLC aperture size (AS), (b) average MU/min (RR). 3D gamma analysis was
performed using a 1%/1mm criteria with a 10% dose threshold.
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Discussion
The linearity between collection efficiency and pulse dose, shown in Figure 17, matches the
relationships found by Chung et al.152 The magnitude of the slope of the 6MV linear fits was
4.44%/(mGy/pulse) for 360Hz (600MU/min). The slope was close to the manufacturer quoted values of
3.79%/(mGy/pulse) compared to previous publications that found slopes closer to 0.10%/(mGy/pulse) for
the 1000SRS51, 158. The difference in measured collection efficiencies from previous publications, may be
due to the different pulse frequency (400Hz vs 360Hz) and measurement technique (two-dose rate
method vs. ion chamber normalization), used in the other studies.
It is important to note that the measured collection efficiencies are specific to the TrueBeam’s
pulse structure. When operating at the maximum dose rate, the TrueBeam delivers radiation in bundles
of 6 equally spaced pulses. When a lower dose rate is used, pulses are dropped. However, the remaining
pulses are not uniformly distributed in the bundles. The longer collection time in the Octavius 4D
measurements, 0.2 seconds spanning 12 bundles, will provide some averaging against the pulse nonuniformity. However, the collection efficiencies shown in Figure 17 will still be unique to the non-uniform
pulse sequence of the TrueBeam, and may not be applicable to other pulse structures.
The pulse structure of the TrueBeam can help explain the change in ion recombination slopes for
the different pulse frequencies, shown in Figure 17 and Figure 18. Chung et al described the difference in
the ion recombination slopes between, pulsed and continues beams8. The slopes of the continuous beams
were steeper than the pulsed slopes. This was due to the buildup of free charge in the chamber, which
will increase general recombination, resulting in a higher ion recombination effect.
Figure 18 shows the magnitude of ion recombination magnitude decreasing as pulse frequency
decreases. When the TrueBeam is operating at the highest dose rate and frequency, the pulse sequence
will be closest to a continuous beam. As the dose rate is lowered, pulses are dropped, reducing the buildup
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of free charge, resulting in a more pulsed-like beam and lower slope. Uncertainty in ion recombination
magnitudes were primarily due to uncertainties in (1) measuring Pion, (2) 1000 SRS measurements, and (3)
the linear regression analysis. Uncertainties in the 6X ion recombination magnitudes were typically larger
than 10FFF, due to the increased collection of leakage in longer (lower MU/min) 1000 SRS measurements.
IMRT analysis
The effects of ion recombination corrections on pass rates were larger for 10FFF compared to 6X.
The larger changes in pass rates were caused by three differences: 1) the pulse dose at the central axis of
the 1000SRS in Octavius 4D was larger for 10FFF(0.760mGy/pulse) compared to 6MV(0.175mGy/pulse),
2) as seen in Figure 18, a change in pulse dose results in a larger change in collection efficiency for 10FFF,
and 3) as seen in Figure 20, the average MU/min of 10FFF plans deviated further from calibration (max
MU/min), compared to 6MV. Changes in pass rates, due to ion recombination corrections, increased with
tighter gamma analysis criteria. Tighter gamma criteria has been recommended for SBRT QA (2%/1mm or
less), due to the high conformity, small field size, and hypofractionation of SBRT treatments.161,

162

Therefore, the tighter gamma criteria, where ion recombination corrections are the largest, will likely be
used in a clinical analysis.
Ion recombination corrections tend to have a uniform effect on the dose distribution. As seen in
Figure 19, the magnitude of the ion recombination effects ((M-C)/M*100%) are mostly uniform in the high
dose region (>10% max dose). There is some non-uniformity in the high dose regions near the high dose
gradients of the profiles. During an IMRT delivery, the high dose gradients are created by exposing a MLC
edge at that location, which results in a dosimetric penumbra with a spatially varying pulse dose. The
change in pulse dose from the calibration conditions are the cause of the increased ion recombination
effects at these locations.
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Although there is some non-uniformity in ion recombination effects across an IMRT field, the
effect tends to be uniform in the high dose region (>10% max dose) – the region that will be included in
the IMRT analysis. Across the subset of LICs measuring in the high-dose region of an IMRT distribution,
ion recombination corrections tend to be uniform within the subset and dependent upon rep-rate only
due to the majority of the dose being delivered to these chambers directly through open MLC apertures
at similar doses/pulse. This uniformity of the ion recombination effect is promising, in that it may be
possible to apply a single calibration factor, which could account for this effect. The daily calibration of
the 1000 SRS presents itself as a natural opportunity for the application of a global calibration factor to
account for ion recombination.
The inclusion of an ion recombination correction in the daily calibrations requires an identification
of the magnitude of recombination prior to delivery. For this reason, the magnitudes of the ion
recombination effects were correlated to average planned MU/min and aperture size – parameters that
will change pulse frequency and pulse dose, respectively. Figure 20 shows the results of this investigation,
where it was found that the magnitudes of ion recombination effects are more strongly correlated to
MU/min.
The stronger correlation suggests that the magnitudes of the ion recombination effects in the
1000 SRS measurements are larger for changes in MU/min, rather than MLC aperture size. The reasoning
for the increased effect can be discerned from the measurement and the process used to calibrate the
1000 SRS. The magnitudes of the dosimetric errors due to the ion recombination effect at any point in the
measurement is equal to the change in collection efficiency multiplied by the dose per pulse. The 1000
SRS was calibrated at the maximum pulse dose and pulse frequency. Lowering the pulse frequency
(MU/min) will change the collection efficiency, while keeping pulse dose large, resulting in a large ion
recombination effect.. Lowering the pulse dose (MLC aperture size) will change the collection efficiency,
however there will be a smaller ion recombination effect compared with the change in frequency. It is
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this characteristic of the ion recombination effects that results in larger dosimetric errors for changing
frequency (MU/min).
Fortunately, ion recombination corrections for changing MU/min can easily be included in the
daily calibration by matching the calibration MU/min to the average MU/min of the plan. This was
implemented in the simple ion recombination corrections. From table 2 it can be seen that the simple
corrections greatly reduce the error due to ion recombination effects. There is still some difference in
pass rates between the complex and simple corrections. This is due to the residual change in MU/min and
aperture size during the IMRT delivery. It may possible to match the average aperture size during
calibration to that of delivery. However, the average aperture size of the plan is not readily available from
the treatment planning system. The added complexity of calculating aperture size may be an unrealistic
burden for clinics looking for a simple fix to ion recombination effects.
Choosing a calibration MU/min higher or lower than the planned MU/min produced pass rates
within 0.5%. On average the lower MU/min calibration pass rates were closer to the complex corrections.
This is likely due to the increased collection efficiency during calibration from the lower MU/min
accounting for the increased collection efficiency from the lower aperture size.
Many clinics use a 6MV flattening filter free mode (6FFF) to treat SBRT patients. The removal of
the flattening filter for 6FFF more than doubles the maximum pulse dose of the machine. The pulse dose
at the central axis of the 1000SRS in the Octavius 4D during calibration would increase from
0.175mGy/pulse to approximately 0.406mGy/pulse, which is less than the 0.760mGy/pulse of the 10FFF
beam. The result is that errors in pass rate due to ion recombination effects would likely fall somewhere
between the 6X and 10FFF results. However, the residual error in pass rates after the simple corrections,
shown in Table II, were similar for 6X and 10FF. Therefore, the residual error in 6FFF measurements would
be expected to follow the same trend.
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The discussion of the ion recombination effects relies on the accuracy of the ion recombination
corrections, which use measured pulse dose and pulse frequency to calculate collection efficiencies.
However, there is an error introduced into the pulse dose corrections when calculating the measurement
collection efficiencies. The true pulse dose is needed to determine accurate collection efficiencies.
However, only the measured pulse dose, which is effected by the collection efficiency, is available leading
to an inherent error in the collection efficiency calculation. The magnitude of this effect can be determined
by (1) assuming a true pulse dose, (2) calculating the corresponding measured pulse dose, (3) using
Equation 11 to re-calculate true pulse dose from the measured, and (4) finally comparing the result to the
original assumed true pulse dose. Using this technique, the error in calculated dose from measured
instead of true pulse dose in the ion recombination corrections is less than 0.1% for all energies.
Conclusion
1000 SRS collection efficiencies increased with decreasing pulse dose and pulse frequency. For a
given pulse dose and a 360Hz pulse frequency (600MU/min and 2400MU/min for 6X and 10FFF,
respectively), the ion recombination was 4.44%/(mGy/pulse) and 5.01%/(mGy/pulse) for 6MV and 10FFF,
respectively. On average, applying complex pulse dose and pulse frequency corrections to 1000SRS
measurements produced small changes in 6X 3D gamma pass rates (1.17+/-1.14% for 1%/1mm gamma
criteria). However, the same corrections resulted in larger changes in pass rates for 10FFF (4.57+/-3.71%
for 1%/1mm gamma criteria), which increased when the plan contained small aperture sizes and a strict
gamma criterion was used. The magnitudes of the change in pass rates were strongly correlated to pulse
frequency (r2=0.96 for 6X and r2=0.78 for 10FFF); therefore, a simple correction method was tested where
the MU/min of the 1000 SRS calibration was selected to match the average planned IMRT MU/min. On
average the pass rates of the simple corrections were within 1% of the complex correction pass rates for
all energies and gamma criteria.
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CHAPTER 5 IMRT QA ANALYSIS – INCLUDING STRUCTURES IN GAMMA INDEX CALCULATIONS
Introduction
A typical IMRT QA measurement involves delivering a treatment plan to detectors and comparing
the dose to that predicted by the treatment planning system (TPS). In practice, if the measured dose
deviates too far from the TPS, the plan fails QA and the treatment does not proceed until the failure mode
is investigated. This QA paradigm operates under the assumption that the fidelity of measured and
predicted dose is correlated to the fidelity of the dose delivered to the patient by the treatment machine
and the TPS predicted dose to the patient. In other words, the better the QA result, the closer the
delivered plan to the TPS. However, research has shown that this assumption is not valid for common
IMRT measurement and analysis techniques. One such publication by Nelms et al. even showed an inverse
correlation, with larger deviations in dose delivery having better QA results163.
In an effort to strengthen the correlation between IMRT QA results and clinically relevant plan
metrics, the inclusion of patient anatomical structures in IMRT QA analysis was investigated. Due to the
wide range of delivery, measurement, and analysis techniques that are used clinically for IMRT QA, a small
subset was chosen for initial investigation. Static gantry head and neck plans were selected to mimic
Nelm’s investigation. Planar measurements in a rectangular solid water phantom were selected to match
TG-119 QA geometry. The gamma analysis was selected as the method of analyzing QA measurements to
match TG-119 and Nelms. In the following sections, the technique for including structures in gamma index
calculations will be discussed and their effect on the correlation between QA results and clinically relevant
plan metrics will be investigated.
Materials and Methods
Prior to including structures in the gamma index calculations, it was necessary to create a test
environment where IMRT QA could be simulated in a controlled manner. The test environment was
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modelled after the work by Nelms et al. and involved creating multiple treatment machines in the TPS
that were slightly modified from one original clinical treatment machine. These modifications would
simulate real-world differences between the dose delivered on a treatment machine and that predicted
by the TPS. Creating these modified real-world machines in the TPS allowed for the simulation of IMRT
QA calculations along with the simultaneous calculation of the delivered and planned dose to the patient.
This allowed for the comparison of IMRT QA results to the deviation between planned and delivered
patient dose. Specifically, this allowed a Pearson correlation analysis to be performed to determine
whether a lower IMRT QA pass rate is correlated with a larger deviation in relevant planning structures
(targets and organs at risk).
Four modified machines were created to simulate real-world deliveries. The modifications
included: 1) doubling the transmission of radiation through the multi-leaf collimators (MLCs), 2) halving
the radiation transmission through the MLCs, 3) smoothing the penumbras that are used to model the
cross-beam profiles of the radiation beam, 4) a double-smoothing of the penumbras. The modifications
were chosen to match Nelms et al., however they also simulate plausible real-world inaccuracies in beam
models. MLC transmission is a commonly adjusted beam model parameter that could easily be set too
high or too low. Excessive beam penumbra smoothing is a mistake that can easily be made if the detector
used to measure beam profiles is too large, particularly for small fields that are often used in IMRT
deliveries.
The original and four modified treatment machines were created in Varian Medical Systems’ (Palo
Alto, CA) Eclipse treatment planning system. The original machine was created using Varian’s golden beam
data. The golden beam data is a collection of machine commissioning data that is distributed by Varian
that represents an average of multiple clinically commissioned machines. The golden beam data used in
this study was for a Varian 21EX machine equipped with a Millennium 120 leaf MLC. The MLC
transmissions were adjusted by changing an editable parameter in the machine configuration. The
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penumbras were adjusted by running the profiles through a moving-average smoothing algorithm in
Matlab. The very smooth penumbras were run through the algorithm a second time. A summary of the
changes made to the four modified machines are shown in Table 6.
Machine
1(original)
2
3
4
5

MLC Transmission
0.016
0.008
0.032
0.016
0.016

80% Width at 10cm depth
9.38
9.38
9.38
9.15
9.02

20% Width at 10cm depth
10.78
10.78
10.78
11.02
11.23

Table 6: Changes made to MLC and beam penumbras to create the modified treatment machines.
To simulate IMRT QA on patients, 9 previously treated head and neck cases were selected and the
dose to the patients were re-calculated using the 5 machine models. Each plan was originally optimized
for a clinical case. The plans were not re-optimized on the new machines, rather the MUs were held
constant to match their clinical plans and new dose calculations were performed. Dose was calculated
with Eclipse’s Pencil Beam Calculation Algorithm(version 8.6.15) using the modified Batho heterogeneity
correction method and a 2.5mm grid size. After the dose calculations were performed, the dose to 95%
of the PTV (PTV-95%) and the maximum dose to the cord (max_spine) were calculated for each plan. The
dose differences between the modified and original plans were normalized to the original planned dose
and recorded as a percentage. These metrics were selected because they were heavily prioritized during
the head and neck plan optimization. A dose deviation in either of these two values could have significant
impact on the tumor control probability or the normal tissue complication probability for an individual
patient.
To simulate IMRT QA measurements, the individual fields for each plan were re-calculated on a
solid water phantom. Dose planes at isocenter, tangential to the beam direction, were exported as DICOM
RT Dose files. The modified dose planes were compared to the original dose planes using a gamma
analysis. The gamma analysis is well described in the literature; however, a brief explanation will be
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provided due to the importance within this work. During a gamma calculation, each measured point is
compared to all planned points. A gamma value is calculated for each comparison. The minimum gamma
value at each measured point determines whether it passes or fails. The gamma value calculation is shown
in Equation 12.

𝛤(𝑟𝑚 , 𝑟𝑐 ) = √

𝑟 2 (𝑟𝑚 , 𝑟𝑐 ) 𝛿 2 (𝑟𝑚 , 𝑟𝑐 )
+
2
2
∆𝑑𝑚
∆𝐷𝑚

(12)

𝛾(𝑟𝑚 ) = 𝑚𝑖𝑛{𝛤(𝑟𝑚 , 𝑟𝑐 )}∀{𝑟𝑐 }

In Equation 12, 𝑟 2 (𝑟𝑚 , 𝑟𝑐 ) is the squared distance between the measured (𝑟𝑚 ) and planned or
2
calculated points, 𝛿 2 (𝑟𝑚 , 𝑟𝑐 ) is the squared dose deviation between those two points, ∆𝑑𝑚
is the squared
2
distance tolerance, and ∆𝐷𝑚
is the squared dose deviation tolerance. The tolerances are user-selected

for each analysis. 3mm distance and 3% dose tolerances are often used and is commonly written as
3%/3mm. In addition, it is common to only include points above a certain percentage of the maximum
predicted dose in the analysis. 10 percent is often used and when combined with the analysis criteria it is
written as 3%/3mm/10% threshold. The results of the gamma analysis are reported as the percentage of
points, above the inclusion threshold, that passed the gamma calculation (had a gamma less than or equal
to 1.0).
A gamma analysis was used to compare all the simulated IMRT QA measurements by using the
dose planes from the original machine as the planned or calculated doses, and the dose planes from the
modified machines as the delivered or measured doses. The gamma analysis was performed using a
custom designed Matlab code using various percent, distance, and threshold values. The range of values
along with the magnitude of steps between the different iterations are shown in Table 7.
A gamma pass rate for each individual field in the plan was calculated and averaged within each
plan to get a per-plan pass rate. Finally, a Pearson r-correlation analysis was performed between the per-
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plan IMRT QA pass rates and the normalized dose differences in the PTV-D95% and max_spine metrics
between the original and modified plans.

Parameter
Threshold
DTA
Dose Deviation

Minimum
5%
1.0mm
0.50%

Maximum
90%
3.0mm
5%

Step
5%
0.5mm
0.50%

Table 7: Various parameters used in the gamma index calculations.
After performing a traditional gamma analysis, a second gamma analysis was performed that
included PTV and spine structures from the TPS. For each patient, the DICOM structure and plan files were
exported from the TPS. The IMRT QA DICOM dose, structure, and plan files were imported into authordeveloped Matlab software. Details of these files along with the Matlab code used to manipulate them
are presented in Appendix A. The structures were used to vary the importance of each point in the field,
the strictness of the analysis criteria, and also to determine which points should be included in the
calculations. A schematic showing the different workflows for the traditional versus structure-dependent
gamma analysis is shown in Figure 21.
Four different methods for including structures in the gamma index calculations were
investigated:
1) Binary – Measurement points would only be included in the final pass rate calculation if they fell
within the beams eye view projection of the structures. Standard gamma index criteria was used.
2) Structure Falloff – All the points within the structure have equal weighting when calculating the
per-field gamma pass rate. Points outside the structure have weighting relative to their distance
from the structure.
3) Structure thickness weighting - Weighting each location’s contribution to the per-field pass rate
based on the BEV thickness of the structure at that location.
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4) Structure dependent Gamma Index criteria – Adjusting the Gamma Index distance-to-agreement
and dose deviation criteria at each location based on the BEV thickness of the structure at that
location.

Figure 21: Schematic showing the workflow for a traditional versus structure-dependent gamma analysis
The simplest way that structures can be included in the gamma analysis is to use them to
determine which measurement points should be included in the final analysis. From a programming
standpoint, this was accomplished by creating a binary mask for each structure where the value was “1”
if the point fell within the structure and “0” if the point was outside the structure. For this study, the spinal
cord and PTV structures were considered. The spinal cord was chosen for normal tissue as it is typically
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the most critical dose limiting structure. An overdose to the spinal cord can cause catastrophic
complications to the patient and in most cases is deemed clinically unacceptable.

Figure 22: Binary structure masks used to delineate region included in the gamma calculation. (A) Overlay
of the structures on a planar dose distribution, (B) PTV only structure, (C) Spine only structure, (D)
traditional 10 percent mask, (E) PTV or Spine structure, (F) PTV and Spine Structure.
The PTV and spinal cord structure maps were combined using logical operators to designate four
different regions that could be included in the gamma calculation: 1) spine only, 2) PTV only, 3) Spine and
PTV, 4) Spine or PTV. An example of the four masks are shown in the Figure 22. The masks were used to
recalculate pass rates, which were subsequentially used to recalculate r-values.
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One fundamental drawback to restricting the analysis using a structure mask is that the radiation
field adjacent to a structure, that will contribute dose to the structure due to scatter, will not be included
in the analysis . The dosimetric accuracy in this region, just outside the target, can often be the most
important due to the task of delivering dose to the target, while sparing the adjacent normal tissue. The
balance between coverage and sparing is accomplished with high dose gradients, which are both difficult
to approximate in the planning system and deliver by the machine.
Partially due to the inherent uncertainties in this region it is typically included in the analysis by
using a 10 percent threshold. As mentioned previously, the 10 percent threshold includes points outside
the structures with equal weighting. However, the radiation spatial dose deposition is not a square
function, rather it typically approximated by a Gaussian type distribution164. Therefore, the closer the
point is to the structure, the larger fraction of its dose will scatter into the structure. These concepts
motivated the inclusion of points outside the structure in the gamma analysis and the weighting of their
contributions based on their proximity to the structure.

(A)

(C)

(B)
Position (cm)

Figure 23: Effect of image dilation using the ball morphological structure element. (A) Original image, (B)
dilated image, (C) dilated intensity falloff outside the original image for different ball height parameters.
To include the additional measurement points, the previously generated structure masks required
expansion with a Gaussian-like falloff. This was accomplished using a Matlab dilation tools, specifically the
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imdilate function. The function dilates an image using a morphological structure element. In this instance,
the structure element was a two-dimensional matrix applied to each pixel in the original image. Based on
the intensity of the pixel, the neighboring pixels may be increased causing the image to expand.
A “ball” structure element was selected for this research. The structure had two parameters:
radius and height. The radius described how far away the dilation occurs from each pixel. The height
described the falloff of the dilation relative to original pixel. The effect of the ball dilation is shown in
Figure 23. The radius and height parameters were adjusted to provide falloff extending to 1.0, 2.0, and
3.0cm (Figure 23.c). Mathematically the dilation was applied to the structure masks to create a normalized
weighting mask, with any point inside the structure having a weighting of one. The weighting value of
each passing point was totaled and divided by the total weighting to obtain a pass rate. Subsequently, rvalues were calculated to compare the weighted pass rates to plan deviations.
Thus far the structure contours have only been used as binary masks to denote the outside border
of the contour. Although this can help to isolate what portion of a field may contribute dose the structure,
the weighting is uniform within the structure in the case of binary masks, and dictated by distance for the
falloff masks. However, the structures can also be used in a non-binary fashion to weight the field within
the structure proportionally to the structure thicknesses (like the falloff). In addition, the structure
thicknesses can be used to adjust the gamma criteria for a point to be considered passing within the field.
For example, the portion of the field near the spinal cord could have a strict passing criterion of 1%/1mm,
while the outer edge of the field could have a laxer 3%/3mm criterion. These two weighting methods,
using structures to weight how much individual points accounts for the overall pass rate and weighting
the strictness of the gamma criteria at individual points, were both were investigated.
The work started with weighting the contributions of each point for the overall pass rate. To
begin, the normalized thickness of the structures was calculated for each field. The results were a
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structure map of the fields with a value of 1 at the thickest part of the structure, 0 outside the structure,
and some scaling in between the extremes. Three different structure maps were considered: PTV, SPINE,
and OR. The AND mask was removed from further analysis as it did not show any major advantage in
previous sections. In the case of the OR structure, the PTV and spine contours were added together, and
the combined thickness was normalized to one.
The importance at each location inside the structures were calculated using the normalized
thickness and Equation 13.
𝐼𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑐𝑒 = 1 + 𝑆𝑙𝑜𝑝𝑒 ∗ (𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠)𝑃𝑜𝑤𝑒𝑟

(13)

The importance points outside the structure were set to zero. Pass rates were calculated in a similar
fashion to falloff masks, where the importance of each passing point was added together and divided by
the total importance of all points summed across the entire field. The pass rate calculations were
performed for different slope and power constants ranging from 0 to 5. Finally, r-values were calculated
that compared the per-plan pass rates for each combination of constants to the plan deviations.
Next, the structures were used to vary the Gamma Index analysis criteria (distance to agreement
and dose deviation). Like the previous work on importance, the thickness of the structures the beam
passed through was calculated at each location in the field and then projected onto the exported dose
planes. Each structure was normalized so that the thickest part of the structure had a value of 1. Also, if
multiple structures added to a number greater than 1 at a single location in the plan, the structure
thickness was set to the maximum value of 1. Figure 24 illustrates an example of structure dependent
passing criteria for two fields. In both fields, the outline of the PTV and the Spinal Cord are shown. The
most significant part of the fields is where the structures overlap. The combined thickness of the
structures is largest at the overlap and therefore a strict passing criteria of 1%/1mm is used. The less
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significant outer areas of the fields that do not include planning structures have a more relaxed 3%/3mm
passing criteria. A 10 percent threshold was used for an inclusion criterion.

Figure 24: Varying the gamma analysis dose and distance tolerances proportionally to the path length
through planning structures. Target (PTV) in orange and spinal cord in blue.
The first structure dependent passing criteria were scaled linearly with the path length through
the structures. Additional calculations were also performed with a structure dependent passing criterial
that scaled as a power function of the normalized path length. By scaling the passing criteria with
progressively higher power functions, this served to further emphasize the regions of the field that passed
through the critical structures. An example of the structure dependent passing criteria scaled as a power
function of 1 (linear) and 3 (cubic) is shown in Figure 25.
For each structure dependent passing criterion, the pass rates of all the modified IMRT QA plans
were re-calculated followed by Pearson r-correlation analysis with the PTV-D95 and max_spine metrics.
Finally, the pass rates of the different calculations were compared to discover overall trends in the data
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and the Pearson r-correlation values were compared to quantify the level of correlations with clinically
relevant plan metrics.

Figure 25: Scaling the structure dependent passing criteria as a function of normalized structure thickness
in the beams-eye-view projection of a treatment field.

Results
The gamma index criterion that produced the best Pearson r-correlation coefficients for the
traditional gamma analysis was 3mm/1.5%/5% threshold. For this criterion, the r-values for the max_spine
was r = -0.847 and PTV-95% was r = -0.849. For comparison, the r-values for the commonly used
3%/3mm/10% threshold criterion were r = -0.717 for max_spine and r = -0.729 for PTV-95%.
To examine the relationship between r-values and the different gamma parameters
(threshold/DTA/percent), one parameter was held constant while the other two were varied. To start, the
distance criteria was set to 3mm, while the threshold and dose difference criteria were varied. The
resulting r-values are shown in Figure 26.
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Figure 26: Pearson r-correlation coefficients between per-plan IMRT QA Gamma Index pass rates and
dose received by 95% of the PTV (PTV-D95%) and the maximum dose to the spinal cord. The distance
criterion in the Gamma Index was set to 3mm, while the dose criteria and threshold criteria were varied.
After examining the effect of varying threshold and dose criterion on the r-values, the same
process was repeated for the distance criterion. The threshold was set to 5%, and the distance-toagreement and dose criterion were varied. The results are shown in Figure 27.
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Figure 27: Pearson r-correlation coefficients between per-plan IMRT QA Gamma Index pass rates and
dose received by 95% of the PTV (PTV-D95%) and the maximum dose to the spinal cord. The threshold
was set to 5%, while the dose and distance-to-agreement criteria were varied.
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The resulting r2-values from using various structure dependent masks are show in Figure 28 and
Table 8. The only mask that showed consistent improvement was the spine mask for the maximum spine
value. Unfortunately, the spine mask resulted in a drop in r-value for the PTV-95%. The AND mask also
showed an improvement in the maximum spine r-values. However, the improvement was less than the
spine mask and the detriment to the PTV-95% r-value was greater.

Figure 28: r2-values comparing pass rates with plan deviations for different binary masks. (A) r2-values
with 3%/3mm, (B) r2-values with 2%/2mm.

Binary Mask
PTV
Spine
Either
Both
10% Threshold

Pearson (r2) correlation values
2%/2mm
3%/3mm
Max_Spine PTV-95%
Max_Spine PTV-95%
0.547
0.521
0.436
0.401
0.577
0.486
0.545
0.443
0.555
0.532
0.451
0.420
0.562
0.456
0.510
0.395
0.552
0.523
0.500
0.493

Table 8: r2 values correlating pass rate with plan deviations. Pass rates were calculated using different
masks to determine which points were included in the analysis.
The results of the r2-value calculations for falloff masks are shown in Figure 29 and Table 9. The
largest r-values for the spine are achieved when using the SPINE and mask with a 2%/2mm analysis
criteria. For this combination of criteria and masks, the r-values showed little sensitivity to the falloff
distance. However, the 1-2cm falloff masks produced better r-values than the structure masks for most
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cases, while the 3cm falloff masks were better for all cases. This suggests that the optimal advantage for
including falloff points, when analyzing the maximum dose the spine occurs, within 2-3cm outside the
structure. A portion of this region, between the PTV and spinal cord, is typically characterized by high dose
gradients that are used to lower the maximum dose to the spinal cord, while maintaining PTV coverage.
It is not surprising that errors in the region could lead to changes in spinal cord dose, and therefore this
area should be included in the analysis.
The PTV metric showed similar trends to the spinal cord; increasing r-value as the falloff increased.
For 3%/3mm, the falloff masks resulted in larger r-values than all structure masks. At 2%/2mm, the
advantage was diminished with some 1cm and 2cm falloff masks underperforming. However, all 3cm
falloff masks produced larger PTV r-values than the 2%/2mm structure masks. Similar to the threshold
analysis, the r-values increased with falloff when more points were included in the calculation. The PTV
and OR masks had larger r-values for 3%/3mm, however all masks tended to perform equally well for
2%/2mm. The 2%/2mm r-values were larger than their 3%/3mm counterparts.

Figure 29: R2-values for structure mask thresholds with falloff point inclusion. Dashed lines are structure
masks with no falloff. Solid bars are 3cm falloff. Dotted bars are 2cm falloff. Striped bars are 1cm falloff.
(a) 2%/2mm, (b) 3%/3mm.
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Spine

0.606
0.605
0.606
0.577

0.564
0.552
0.534
0.486

0.568
0.565
0.574
0.545

0.525
0.516
0.501
0.443

3
2
1
None

0.609
0.566
0.541
0.555

0.561
0.528
0.512
0.532

0.578
0.529
0.472
0.451

0.564
0.514
0.449
0.420

3

0.608

0.563

0.559

0.505

2

0.595

0.533

0.542

0.475

1

0.595

0.506

0.544

0.446

None

0.562

0.456

0.510

0.395

AND

3
2
1
None

OR

PTV

Binary Mask

Pearson (r2) correlation values
2%/2mm
3%/3mm
Falloff(cm) Max_Spine PTV-95%
Max_Spine PTV-95%
3
0.608
0.561
0.578
0.561
2
0.559
0.518
0.521
0.500
1
0.530
0.496
0.455
0.425
None
0.547
0.521
0.436
0.401

Table 9: Correlation coefficients between DVH deviations and gamma pass rates calculated using a
structure mask threshold with the inclusion of some points outside the structure. The falloff term
represents how far outside the structure mask that points are included in the calculation
The results of the r2-values for the structure-weighted importance calculations are shown in
Figure 30 and Figure 31. The first column of all the plots have a slope of zero. Per Equation 13, this results
in an importance of 1 across the entire mask, which creates a binary mask. Therefore, the first columns
match the data shown in Table 8.
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Figure 30: Spine (A-C) and PTV (D-F) r2-values for structure dependent importance weighting of each
point in a 3%/3mm gamma calculation.
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Figure 31: Spine (A-C) and PTV (D-F) r2-values for structure dependent importance weighting of each
point in a 2%/2mm gamma calculation.
The comparison between deviations in the maximum dose to the spinal cord and the per-plan
pass rates using three common clinical gamma analysis and the linearly scaled structure dependent
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gamma criteria are shown in Figure 32 and Figure 33, respectively. The corresponding Pearson rcorrelation coefficients are shown in Table 10. The comparison between deviations in dose to 95% of the
PTV and the per-plan pass rates using various gamma analysis criteria are show in Figure 34 and Figure
35. The corresponding Pearson r-correlation coefficients are shown in Table 11.
Utilizing a higher power scaling technique increased the correlation between passing criteria and
dose objectives. Correlation coefficients increased an average of 0.008 between linear and cubic scaling
techniques. However, using a power scaling technique larger than cubic did not improve the correlation
coefficients.
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Figure 32: Per-plan IMRT QA pass rates versus deviations in maximum dose to the spinal cord for different
gamma analysis passing criteria.
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Figure 33: Per-plan IMRT QA pass rates versus deviations in maximum dose to the spinal cord for structure
dependent gamma analysis passing criteria.
Pearson r-correlations between IMRT QA Pass Rates & Max Cord Error
Structure
Analysis Criteria
3% / 3mm
2% / 2mm
1% / 1mm
Dependent
Pearson r - values
-0.717
-0.720
-0.750
-0.831
Table 10: Pearson r-correlation coefficients (r-values) between per-plan IMRT QA pass rates and
deviations in maximum dose to the spinal cord for various gamma analysis passing criteria.
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Figure 34:Per-plan IMRT QA pass rates versus deviations in the dose to 95% of the PTV for different gamma
analysis passing criteria.
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Figure 35: Per-plan IMRT QA pass rates versus deviations in the dose to 95% of the PTV for structure
dependent gamma analysis passing criteria.
Pearson r-correlations between IMRT QA Pass Rates & PTV D95 Error
Structure
Analysis Criteria
3% / 3mm
2% / 2mm
1% / 1mm
Dependent
Pearson r - values
-0.729
-0.703
-0.711
-0.812
Table 11: Pearson r-correlation coefficients (r-values) between per-plan IMRT QA pass rates and
deviations in dose to 95% of the PTV for various gamma analysis passing criteria.

Discussion
Figure 26 shows that lower thresholds produced the best correlations. Above a 75-80% threshold,
the correlation breaks down entirely. For those thresholds, a large portion of the treatment field that
passes through the spine and PTV has been ignored, causing the correlation to break down.
For the thresholds below 40%, the correlation may more strongly depend on the portions of the
field that fall near a target-critical structure junction. Some example locations for H&N cases would be
between PTV-cord, PTV-parotid, and PTV-normal tissue. At these locations, dose gradients are usually
high, resulting in low doses to the OAR and just enough coverage on the PTV to obtain a good DVH. These
voxels play an important role in determining the max dose to the spine and the coverage of the PTV. As
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the threshold increases, fewer of these points are included in the analysis, causing the correlation to break
down.
For a given threshold, a stricter dose criterion tended to produce stronger correlations. To
visualize the reason why this happens, it is useful to look at the 0.5%/3mm/10% threshold and the
3%/3mm/10% threshold data on the same plot (Figure 36). The 3%/3mm data has a considerable amount
of points above 95% and a few that are 100%. The truncated nature of gamma analysis (with a maximum
100% pass rate), may lead to poor correlations with plan metrics due to too many QA results hitting this
upper limit.

Figure 36: Comparison between per-plan Gamma Analysis pass rates for 0.5%/3mm/10% threshold and
3%/3mm/10% threshold analysis criteria.
For the head and neck cases in this study, the DTA criteria did not have a strong effect on the rcorrelations and AUCs. However, in general the smaller the DTA the worse the correlation. This may have
been due to the types of modifications that were introduced into our machines. The modifications were
spatially “smooth”; they had a gradual effect on the overall dose distribution. If the modifications had a
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higher spatial gradient (moving an entire leaf bank), then modulating the DTA criteria may have a greater
effect on the pass rate correlations to dosimetric plan metrics.
There are a few features of the masks, shown in Figure 22, which can be used to understand their
behavior. The PTV and 10 Percent masks look very similar with a few notable differences in that the 10
percent mask is slightly larger and filled in the middle. The size comes from the dosimetric objectives of
the radiation treatment. If the goal is to treat the PTV with full dose, the 10 percent line must trace outside
the PTV, thus the 10 percent mask is larger.
The middle filling of the 10 percent mask is a product of the technique used in its creation. The
technique starts by determining the area in which dose is greater than 10% of the maximum. Instead of
only using this area as the mask, it also includes any points in between two areas that are greater than
10% of the maximum dose. The idea is that when analyzing an IMRT field it is equally important to look at
where the radiation is and is not being delivered. If a low dose region exists in between two high dose
regions, it is likely that there is a critical structure which is being avoided. Figure 22.a demonstrates this
phenomenon where the dose surrounds the spinal cord. If only the greater than 10% areas were
considered, the dose to the spinal cord would be ignored, which is not ideal.
The PTV and OR masks follow the same trend as the previous threshold analysis: as more points
are included in the analysis, the r-values improve. Furthermore, when a spine mask was used, the r-values
improved for the spine, while decreasing for the PTV, showing the importance of adequate analysis of the
entire structure. When the AND metric was used to further reduce the size of the analysis area, the spinal
cord r-values decreased.
Based on this data, it appears that binary masks may have some utility for analyzing individual
structures, especially if those structures occupy a small portion of the field. However, care should be taken
to ensure that enough measurement points are included in the analysis to cover the entire structure.
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Overall, falloff weighting was able to produce better r-values compared to binary mask weighting.
For the PTV-95% metric, a 3%/3mm and 3cm falloff from the OR mask was optimal. For the Spine_Max
metric, a 2%/2mm and 3cm falloff from the OR mask was optimal. This supports the use of a lower dose
threshold to include data outside of the PTV in the gamma analysis.
For almost all masks and gamma criteria, the r-values improved when the structure dependent
importance weighting was included in the gamma analysis. As slope increased, the structure metrics
tended get better at first, however most reached a critical point after which an increase in slope led to a
decrease in the r-values. The effect of increasing the power was less beneficial, in that r-values were
optimized for a power of 1. Some did show improvement for a power of 2, but most r-values became
smaller for powers of 3 and above.
For the spine, the PTV and OR masks performed similarly to the SPINE mask. The magnitudes of
the r-values were similar across the masks, and the optimal power and slope constants were also similar.
For the 2%/2mm criteria, the optimal slope and power values were 2 and 1, respectively. For the 3%/3mm
criteria, the optimal slope and power values were 3 and 1, respectively.
For the PTV structure, the PTV and OR masks produced better metrics compared to the SPINE
mask. The optimal slopes and powers were 2 and 1 for 2%/2mm; 3 and 1 for 3%/3mm. This matched the
optimal values for the spine, suggesting that a single set of importance weighting should be used in
conjunction with a large mask (ex. 10 percent threshold) to produce optimal r-values for various
structures.
When the structures were used to modify the gamma analysis criteria, similar trends were
observed to the structure dependent importance weighting. Like the importance weighting, utilizing a
power scaling technique was beneficial up to a cubic-power, however higher powers did not show the
same benefits. The structure dependent gamma criteria produced r-values that were stronger than any
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traditional gamma analysis criteria (1%/1mm, 2%/2mm, 3%/3mm). As the structure dependent criteria
ranged between 1%/1mm to 3%/3mm throughout the treatment field, strictness of the passing criteria
was equal to or less than the 1%/1mm traditional global criteria. This suggests the improvement in rvalues were not just from increasing the strictness of the gamma analysis criteria. Rather, preferentially
weighting the gamma analysis using patient structures, either through importance weighting or gamma
criteria weighting, can have a positive effect on the correlation between pass rates and dosimetric plan
metrics.
Conclusion
Choosing appropriate gamma criteria and including structures in the gamma analysis were both
able to improve the correlations between per-plan IMRT QA pass rates and deviations in dosimetric plans
rates. However, the commonly used 3%/3mm/10% threshold performed favorably as well. Analysis
techniques that produced many pass rates near to 100%, tended to have poorer correlations than those
that were more evenly distributed. This may be a fundamental flaw in the current clinically practice, where
IMRT QA tests are designed with high pass rates tolerances (ex. 95%). This study was limited given the
scope of the types of IMRT plans studied (static-gantry angle head and neck) and the types of errors (MLC
transmission and penumbra), however the various techniques that were used are applicable to other
errors and static-gantry angle treatment types.
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CHAPTER 6 SINGLE-ISOCENTER MULTI-TARGET IMRT CRANIAL SRS COMMISSIONING
Introduction
Elements Multiple Brain Mets SRS (MBMS) is a site-specific planning system for treating multiple
cranial targets that was developed by Brainlab (Brainlab, Munich, Germany). Unlike conventional planning
systems that are designed to treat a wide range of anatomical sites, MBMS creates single-isocenter multitarget (SIMT) linac based cranial stereotactic radiosurgery (SRS) plans, using non-coplanar dynamic
conformal arcs. SIMT has the potential to create plans with similar organ at risk (OAR) sparing and target
coverage, while reducing treatment times compared with multiple single-target plans.165-168 The specificity
of the MBMS allows for an optimization algorithm that can focus on important cranial SRS metrics. The
optimizer can also overcome typical linac based cranial SRS planning shortfalls, like the bridging of dose
between two targets.
One drawback of the specificity of the TPS being able to only produce one type of plans for a
specific anatomical site, is that the commissioning physicist is unable to perform an AAPM Task Group 119
type test of the system to compare their commissioning results for various anatomical sites to other
institutions.96 Furthermore, MBMS may be commissioned at the start of an institution’s linac-based cranial
SRS implementation so there may not be any internal data for comparison. In this work, the MBMS
commissioning experience on an Elekta Versa HD (Elekta AB, Stockholm, Sweden) will be presented which
can be used for guidance as well as a baseline for comparison.
Materials and Methods
Generating Beam Model
Beam model measurements included: PDDs, profiles, scatter factors, collimator transmission, and
dynamic leaf shift. Data collection followed Task Group 106 methodology.169 All measurements were
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made in Sun Nuclear’s (Sun Nuclear Corporation, Melbourne, FL) 3D water tank with Sun Nuclear’s 0.125cc
chamber, EDGE detector, or PTW’s (PTW-Freiburg, Freiburg, Germany) microDiamond detector. A SNC
0.125cc chamber was used as a reference chamber to normalize the data for fluctuations in linac output
when scanning profiles and PDDs.
The water tank was set up to the central axis of the beam using a ray tracing procedure. For profile
measurements, the tank was shifted 0.25cm (1/2 leaf width) in the jaw direction, so the detectors
intersected a multi-leaf collimator (MLC) leaf tip instead of junction between two MLC leaves. For output
measurements, a Daisy-Chain method was used to calibrate the microDiamond for small field
measurements170. The SNC 0.125cc was used to measure output factors down to a 3.0cm field size, after
which it was cross calibrated to the microDiamond chamber to measure output factors down to 1.0cm.
microDiamond measurements were performed without corrections, which is examined in the discussion.
Beam data was collected for energies 6X, 6FFF, and 10FFF. The measured data was processed by
Brainlab to calculate leaf shifts, tongue and groove sizes, source functions, and radial factors.
After beam model parameters were measured and calculated, machine models were created for
each energy. Machine models require department specific parameters (machine name, coordinate
convention, etc.) along with machine specific information such as dose rate and maximum gantry speed.
The machine type parameters were collated from 3 sources: 1) Versa HD manuals, 2) Monaco manuals
(provided by Elekta), and 3) settings in existing hospital planning systems (Pinnacle). Following the
creation of the machine model, the energy specific beam models were created for the three energies.
Prior to final saving of the model, the system performed a secondary check for the data to help protect
against non-realistic values.
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Validation
AAPM Task Group 53 was used to guide the treatment planning system (TPS) validation.109 The
data transfer from Elements to the record and verify system (Mosaiq) was tested using various test plans.
Subsequent data transfer to the linac and on-board imagers was tested. Data fidelity was checked at each
step of the transfer.
Initial validation of the MBMS version 1.5 beam model was done using the Beam Model
Verification module, included in the Elements software, which allows the calculation of single fields on
phantoms. Dose was calculated with a Pencil Beam Algorithm utilizing a 1mm grid size. A virtual water
phantom with density 1.0g/cm3, simulating a water tank, was generated in Matlab and imported into
Elements. The point dose, output factors, depth dose, and profiles were calculated using the same
geometry as the commissioning measurements and verified against measured data.
Following beam model verification, the validation of typical clinical deliveries was performed.
Since Elements is a template-based software, various prescription and beam arrangement template
protocols were generated to cover the range of expected clinical cases. Prescription protocols of 19Gy x
1fx, 8Gy x 3fx, and 6Gy x 5fx were created with various minimum target coverages of 95%, 97%, and 99%
for a total of nine protocols. Beam templates for 2, 3, and 5 different couch angles were created. Two
versions of each protocol were created: 1) all the couch angles on one side of the gantry, 2) couch angles
on both sides with symmetrical arrangement. MBMS automatically mirrors one-sided protocols if the
target is on the other side of the brain, therefore the generation of both left and right sided protocols was
not needed.
To test the protocols, previously treated cranial SRS patients treated within the hospital system,
were re-planned in MBMS. All initial plans were 1 fraction treatments with the same prescriptions ranging
from 15Gy to 20Gy covering 95% of the target. Fourteen clinical targets were studied ranging from 0.27cc
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to 7.32cc. Plans had between 2-5 couch angles and 1-5 targets. Each plan was recalculated for three
energies: 6X, 6FFF, and 10FFF. While it was known that 10FFF would not be used for cranial treatments,
the energy was commissioned in anticipation of different anatomical sites for use with Elements (ex.
Spine). Regardless, it is recommended that at least two energies be commissioned simultaneously to allow
cross-comparison between results, which can be helpful with troubleshooting any inconsistencies that
arise during validation.
𝐼𝐶𝐼 = (𝑇𝑉 × 𝑃𝐼𝑉)/(𝑇𝑉𝑃𝐼𝑉 2 )

(14)

𝐺𝐼 = 𝑃𝐼𝑉ℎ𝑎𝑙𝑓 /𝑃𝐼𝑉

(15)

where, ICI = Paddick Inverse Conformity Index
GI = Gradient Index
TV = Target Volume
PIV = Prescription Isodose Volume
TVPIV = Target Volume covered by Prescription Isodose Volume
PIVhalf = 50% Prescription Isodose Volume
Plan quality was evaluated using Paddick inverse conformity index (ICI – Equation (14)), gradient
index (GI – Equation (15)), and Brain V12Gy (volume of normal brain getting dose of 12Gy or more) to get
an understanding of the limits of the system.171, 172 A subset of plans (volumes ranging from 0.89cc to
7.32cc) were exported to Mosaiq for dosimetric validation on the Versa HD. Dose validation was
performed using a combination of Gafchromic film, microDiamond point dose measurements, and
SRSMapcheck. All measurements were done using StereoPHAN with proper inserts. To set up the
StereoPHAN in MBMS, multiple CTs were acquired will the different measurement inserts using a Philips
Brilliance Big Bore CT scanner (Andover, MA) with 1mm slice thickness. The StereoPHAN was indexed to
the CT couch while scanning with different inserts to prevent movement. This allowed for easy comparison
of cross-modality measurements (ex. Gafchromic Film and SRSMapcheck) using the same DICOM
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coordinates. The phantom was imported into MBMS and assigned a uniform density of 1.20g/cm3 as
specified by the StereoPHAN manual.
Initial dose validation of the phantom was performed by measuring simple square fields on the
Versa HD at various gantry/couch angles. This confirmed the model within the TPS was correct and also
verified the angular and field size dependencies of the various detectors matched manufacture’s
specifications.
Subsequent dose validation was performed for MBMS plans. When measuring single target plans,
the StereoPHAN central axis was aligned to the in-room lasers, so that the dose cloud was positioned on
the central axis of the detector. However, for multi-target plans, where target dose clouds are often
located away from isocenter, the phantom was shifted for QA measurements to align the target dose
clouds with the detector central axis. This corresponding shift was done in the Elements software by
moving the beams isocenter position on the phantom. Equation 16 was used to determine the new
measurement isocenter position (𝐼𝑚 ), from the detector central axis (𝐼𝑑 ), target position (𝐼𝑡 ), and
treatment isocenter (𝐼𝑝 ). All positions were 3 x 1 matrices (x,y,z). The measurement and detector
positions were DICOM coordinates on the phantom CT. The target and plan isocenter were DICOM
coordinates on the patient planning CT.
𝐼𝑚 = 𝐼𝑑 − 𝑅𝑦 (𝜃 ′ ) (𝐼𝑡 − 𝐼𝑝 ) , where 𝜃 ′ = 𝜃𝑝 − 𝜃𝑚

(16)

The rotation matrix was included for measurements that were performed at a different couch
angle than planned. For example, some measurements were done at couch angle zero to minimize angular
dependencies of the detectors. The 3 x 3 matrix is an elemental rotation matrix about the y-direction
(anterior-posterior) where 𝜃 ′ is the difference between the planned (𝜃𝑝) and measurement (𝜃𝑚 ) couch
angles.
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To apply shifts during measurements, the phantom was first set up to the lasers and calculated
shifts (𝑅𝑦 (𝜃 ′ ) (𝐼𝑡 − 𝐼𝑝 )) were manually typed into the Elekta iGuide software. The iGuide software used
the translational movements on the 6 Degree of Freedom Hexapod couch to apply the shifts. For shifts
outside of the Hexapod range of motion, the iGuide software prompts the user to manually shift the 3dimensional Elekta Precise table to get close to the intended position, before automatically performing
final adjustments with Hexapod couch.
In addition to validating dose on MBMS patient plans, an End-to-End (E2E) test was performed
using the StereoPHAN phantom. The E2E test incorporated all clinical steps from initial imaging, fusion,
contouring, planning, data export to record and verify system, quality assurance of the treatment plan,
positioning using image guidance, and treatment delivery. The MR target insert, consisting of three
spherical cavities (two 10mm diameter and one 20mm diameter) filled with mineral oil, was imaged using
MRI and CT scanners. The images were co-registered in MBMS and targets were contoured on the MR
image set and compared with the CT data set to validate geometric accuracy. A 5-table angle 6FFF MBMS
plan was created that delivered 18Gy in one fraction to each target. The plan was exported to Mosaiq for
delivery and pre-treatment plan QA was performed. The in-room imaging system was used to align the
StereoPHAN with the Gafchromic film insert. The treatment plan was delivered to a Gafchromic film plane
that intersects all the targets. Point dose measurements were taken with microDiamond at the center of
each target. Gafchromic film and microDiamond measurements were compared to dose calculated by
MBMS plan.
Following the commissioning of MBMS version 1.5, an updated version of the software 2.0 was
released. A new optimizer was tested for clinical use with the following major changes: 1) MLC margins
can vary between -3mm to 3mm and change between arcs (previously a universal 1mm margin was used),
2) jaws can partially cover an MLC leaf (previously fixed to the leaf edge), 3) optimizer cost function
focused on dose falloff as well as conformity (previously only conformity). The commissioning plans were
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re-optimized with the new software and a student t-test was used to compare plan quality metrics for the
two optimizations. In addition, a subset of the plans were delivered to an SRSMapcheck and
microDiamond in a StereoPHAN on a Versa HD to verify dose.
Results
Beam Model – Scatter Factors
Comparisons between measured and calculated scatter factors measured at 100cm source-tophantom distance and 10cm depth were performed (Figure 37). Square fields were within 1% of Elements
calculated values. The absolute measured scatter factors are shown in Table 12 for comparison.
Field Size
6X
6FFF
10FFF
(cm)
1.0
0.677 (3) 0.696 (3) 0.680 (4)
2.0
0.806 (2) 0.830 (3) 0.843 (4)
3.0
0.847 (3) 0.872 (2) 0.894 (3)
4.0
0.879 (1) 0.901 (4) 0.923 (1)
6.0
0.928 (2) 0.945 (2) 0.958 (2)
8.0
0.970 (2) 0.977 (2) 0.982 (4)
10.0
1.000 (0) 1.000 (0) 1.000 (0)
Table 12: Measured scatter factors at 100cm SSD and 10cm depth. Field size is nominal setting on the
VersaHD. Bracketed numbers show the 2*sigma uncertainty in the last digit.
The uncertainty in the measurements were calculated as two times the standard deviation of
repeated measurements on separate days. It is important to note that scatter factors measurements were
required without any leaves open behind the jaws. However, 1cm field size calculations could only be
performed with an additional two leaves open behind each jaw that matched the width of the open leaves
defining the field. Colloquially known as guard leaves, these will increase the dose for a 1cm field by
approximately 4%. This discrepancy likely contributed to the small (<10mm) single-target modeling error
that is discussed in the dose validation section.
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Figure 37: Comparison between commissioning and calculated scatter factors at 100cm source-tophantom distance and 10cm depth. All scatter factors were normalized to unity for a 10cm x 10cm field.
Beam Model – PDDs & Profiles
The difference between the measured and calculated PDDs and profiles for select 6FFF square
fields and depths were compared (Figure 38 and Figure 39). The PDDs and Profiles were normalized to
dmax and the central axis, respectively. A PTW-60019 microDiamond chamber was used for PDD scanning.
Large field profiles, used in beam model generation, were scanned with the Sun Nuclear 0.125cc chamber.
Subsequent profiles down to 1cm field size were scanned with both the microDiamond and EDGE detector
for beam model validation. Measured PDDs were within 0.5% of calculated past dmax for all energies.
Measured Profiles for all energies were within 0.5% of calculated for typical cranial off-axis treatment
distances (<10cm).
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Figure 38: Comparison between commissioning and calculated 6FFF percent depth doses (PDDs) at 100cm
source-to-phantom distance for selected field sizes.

Figure 39: Comparison between commissioning and calculated 6FFF diagonal profiles at 100cm source-tophantom distance for select depths.

Beam Model – Collimator Penumbra
The measured in-plane (jaw) penumbra was larger than the cross-plane (MLC) penumbra, which
is similar to previous publications.129 The difference between the measured and calculated penumbras is
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shown in Figure 40. All profiles were normalized to the central axis for comparison. The differences in the
jaw direction were typically <2.0%, while the differences in the MLC direction were <10.0%. The penumbra
differences were similar for different field sizes and depths. A single penumbra model is used for both the
MLC and Jaws, which resulted in a larger difference in the MLC direction.

Figure 40: Difference between the measured and calculated 6FFF collimator penumbras at 100cm sourceto-phantom distance, 10cm depth for a 3cm x 3cm field size. The discrepancy is smaller in the jaw direction
(A) compared with the MLC direction (B).
Beam Model – MLC DLS and Transmission
The measured MLC transmissions and dynamic leaf shifts are shown in Table 13. The 10FFF
transmission was slightly lower than 6X and 6FFF, however this is offset by the larger dynamic leaf shift
causing increased transmission near the field edges. The transmission with the jaws closed (jaws and MLC
combined) was zero percent for all energies.
6X

6FFF

10FFF

Transmission

0.4%

0.4%

0.3%

Dynamic Leaf Shift

0.15

0.22

0.26

Table 13: Measured multi-leaf collimator (MLC) transmission and dynamic leaf shifts.

98
MBMS plan quality
The MBMS plans had GIs smaller than 5.0 and ICIs smaller than 1.5 for target diameters larger
than 10mm. For targets smaller than 10mm, the GI increased above 5.0 for SIMT plans as shown in Figure
41. This increase occurs at approximately two times the multi-leaf collimator (MLC) width of the Versa HD
(5mm at isocenter) and may be different for other MLCs. Chea et al. found a similar increase in GIs above
5.0 for target smaller than 0.1cc, which corresponds to a diameter of approximately 0.6mm173. The lower
cutoff may have been due to their use of Varian’s HD-MLC, which has a width of 0.25mm at isocenter at
the central axis. However, Liu et al. found this GI increase to occur at approximately 0.3cc (0.8mm
diameter) for single-target VMAT plans that were generated for Varian’s HD-MLC, which is close to what
was observed in this study174.

Figure 41: Dose metrics for single-isocenter multi-target plans of different target sizes created with MBMS
compared with Gamma Knife (GK).
Due to the small size of the targets, an increase in GI corresponding to a larger 50% prescription
isodose volume, has a smaller effect on V12Gy compared with a larger targets. Therefore, a higher GI is
often deemed clinically acceptable, when treating small targets which may add a small volume of V 12Gy
with additional larger targets. Also when treated in isolation small relative amounts of V12Gy may be
clinically irrelevant depending in terms of risk of radionecrosis and focal neurological deficit.175, 176 ICIs
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tended to be worse for irregularly shaped targets, which matches previous work showing SIMT deliveries
having better normal tissue sparing for spherically shaped targets.177
Compared to the Gamma Knife plans, the MBMS plans tended to have better ICIs and worse GIs.
On average the MBMS V12Gy was 0.998cc +/- 4.179cc lower than the Gamma Knife. However, the Gamma
Knife plans often had lower V12Gy values than the MBMS plans, which is reflected in the large standard
deviation about the average.
MBMS Dose Validation
Measured MBMS microDiamond doses had a mean difference of 0.31% compared to MBMS
calculated dose with a maximum difference of 2.84%. Average per-field pass rates measured with the
SRSMapcheck in the StereoPHAN were 98.0% with a minimum of 95.5% using a 2%/1mm/10% threshold.
E2E testing showed similar results, with a microDiamond measurements within 1.5% of planned, and
Gafchromic film pass rates of 98.6% and 99.6% using a 10% threshold and 3%/1mm and 5%/1mm gamma
criteria, respectively. Figure 42 shows the Gafchromic film results in the axial plane for the 3 target E2E
plan. Most of the remaining failing points with the 5%/1mm criterion were due to the pin-holes in the
Gafchromic film, which were used for registration.
When a plan was generated for only a single target, the microDiamond measured dose began to
increase >3% for targets below 10mm, possibly due to larger effect of guard leaves in smaller targets.
However, this dose discrepancy was not observed when the smaller target was included in a plan with
other targets. Attempts were made to manually adjust beam model scatter factors to better model single
target dose, however it was found that improvements in single-target dose modeling would lead to larger
errors in multi-target plans. Due to the multi-target purpose of MBMS, the decision was made to prioritize
multi-target dose modeling over single-target.
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Figure 42: Axial film results of the end-to-end test. (A) Isosdose overlay between Elements-predicted and
film-measured dose. (B) Line profile between two targets (green line in (A)).
MBMS Version 2.0
The new optimization algorithm in MBMS Version 2.0 reduced ICIs by 0.05+/-0.10 [P < 0.01] and
GIs by 0.40+/-0.65 [P < 0.01], with no significant changes to the PTVmin [P > 0.10]. Whole brain V12Gy was
reduced by an average of 2.39cc [P < 0.01]. The resulting reduction in whole brain V12Gy is visualized in
Figure 43 where the new optimizer eliminates the 12Gy dose-bridging between the two targets. A similar
improvement in plan metrics in MBMS v2.0 has been observed in previous publications178. Average
SRSMapcheck pass rates were 98.7% [97.0% - 99.8%] using relative gamma analysis (2%/1mm/10%
threshold). Measured microDiamond dose was within 1.40% of calculated for all targets.

101

Figure 43: Plan comparisons between: (A) MBMS v1.5 and (B) MBMS v2.0. The updated algorithm
removes the 12Gy dose-bridging.

Discussion
Due to the small field sizes used in cranial SIMT deliveries, small misalignments of the water tank
may lead to sharper falloff in PDDs and lower scatter factors. For PDD measurements, the tank should be
aligned to the beam axis. This will require that the water tank deviates from true level as gantry sag on
the VersaHD causes the beam axis to point slightly towards the gun direction. The alignment of the beamaxis can be verified by scanning profiles at multiple depths and ensuring the central axis of the profiles
remains unchanged. Furthermore, the beam profiles should be scanned immediately prior to small field
scatter factor measurements to position the detector at the local maxima within the field.
IAEA TRS-483 provides an exhaustive list of small field correction factors for various chambers.179
These can be used to correct small field scatter factor measurements, particularly when comparing results
between detectors. If correction factors are used for commissioning measurements, they should also be
used for validation measurements. Published correction factors are typically reported for reference
conditions on the central axis, while MBMS validation measurements will likely be off-axis. The correction
factor for a given field size under reference conditions may differ from validation measurement, due to
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changes in small field phenomena (source blocking, volume averaging, angular dependence, etc.).
Therefore, it is recommended to validate small field dosimetric accuracy with multiple detectors.
In this work, small field correction factors were not applied to the measurements. Based on TRS483, the microDiamond will over-respond by approximately 1.5% for a 1.0 cm field size. Additional
publications have suggested this over-response may be up to 3.4% for a 6FFF beam on the VersaHD with
a 1.0 cm field size180. This over-response will lead to an increase in the measured small field scatter factors
and thereby a reduction in the delivered dose. This matches the measured E2E film results which were
found to be 1.5% lower than the predicted TPS dose for the 1.0cm target (Figure 42). Given the expected
clinical prescriptions for the small targets, this lower dose was deemed to still be ablative to the target,
while the clinical organs-at-risk dose would be within tolerance.
TPS validation of water tank measurements was important for discovering fundamental
limitations of calculation model. Specifically in Elements, a discrepancy was found in how the Versa HD
MLC penumbra is modeled. It was found that error in the MLC model could lead to reduced pass rates for
single field measurements at couch zero with a small collimator rotation. In these instances, the modeling
error could have coherent summation leading to failing measurements along the edges of the targets.
However, when the cumulative target dose from all fields in the MBMS plan was measured with couch
rotations applied, the MLC modeling error had little effect on the overall dose distribution.
One of the unique challenges of SIMT commissioning was positioning the detector at the center
of an off-axis target. This was accomplished by manually applying shifts with the Hexapod couch, which
has been shown to have sub-millimeter accuracy.181 An initial hurdle to this technique was determining
how the Hexapod coordinate system related to real-word and TPS coordinates. It is recommended that
coordinate correlations be determined ahead of QA measurements by either: 1) an investigation of
documentation and system settings, or 2) guess-and-check method where shifts are applied and the
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resulting real-world shifts are recorded. During commissioning the guess-and-check method was used to
determine the coordinate relationships between: 1) treatment planning system, 2) six degree of freedom
couch, 3) in-room imaging systems, 4) QA analysis software.
The arclength error produced by a rotational error will increase as targets get farther from the
central axis. For small angles, the linear error will equal the radius times the angle in radians. AAPM Task
Group 142 recommends a 1o collimator tolerance.120 A 1o collimator error would create a 0.87mm linear
error for a target 5cm away from the central axis. To reduce this error, a stricter 0.5o collimator tolerance
was adopted, which was found to be consistently achievable on monthly QA. Furthermore, TG-142
requires a 0.5o couch tolerance for SRS/SBRT, however the clinical display only shows integers. This was
overcome by enabling the “PSS” page in service mode, which reports angles in 0.1o increments. Studies
show that target coverage degrades substantially when rotational errors approach 2o.182 Therefore,
minimization of both mechanical and patient setup errors is critical. This can be partially accomplished by
real time image guidance at each couch angle and positioning the patient with a six degree-of-freedom
robotic couch183.
When creating beam and prescription protocols, it was best to create one prescription and beam
protocol and fully test the planning and delivery. Once fully tested, the protocols could then be copied
and modified as needed. This would help prevent unnecessary time fixing issues that may propagate
through all the protocols if they are generated prior to testing.
The two main advantages of SIMT are efficiency in planning and delivery. For a multi-target cranial
case without SIMT, each target would have a separate isocenter with its own set of non-coplanar arcs.
The person designing the treatment would have to manually optimize the arc, gantry, and couch angles
appropriately so that the treatment of one target does not overlap with another target. The issue of dose
overlap in multi-isocenter plans is twofold: 1) overlapping dose will increase the dose to other targets,
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which may cause overdosing and increase the GI and ICI metrics, 2) dose overlap in the normal brain
tissue, particularly in the high dose region, will increase the brain V12 which may lead to normal tissue
complications
For a two-target treatment, it is typically easy to prevent cross-target dose overlap by viewing
each arc in the beams-eye-view and adjusting the couch and gantry angles to avoid projecting dose
through the other target. However, this manual optimization quickly becomes more complicated when
the number of targets increases. This increased complication typically results in increased variation
amongst different planners, as often more experienced planners are better able to handle this manual
optimization. Regardless of the abilities of the planner, this manual optimization is tedious. Furthermore,
some overlapping of dose between targets is inevitable due to scatter within the patient. Therefore,
optimizing individual target doses then combining them may not produce the optimal plan for each target
when the summated dose is considered.
The Elements MBMS optimization solves both problems of angular optimization and dose
overlapping by optimization all targets simultaneously. What may have taken multiple hours, or even
days, to plan can now be accomplished in less than 10 minutes. Furthermore, the time on the treatment
machine can be dramatically reduced due to the need to only setup the patient once for a single isocenter.
A typical clinic, treating with a Versa HD, will take 30-45 minutes per isocenter for a non-coplanar cranial
SRS case. A 5-target treatment would be 2.5 – 3.75 hours for a multi-isocenter treatment versus 30-45
minutes for a SIMT delivery. This is of particular importance to the patient who is immobilized in a rigid,
and often uncomfortable, aquaplast mask to prevent intra-fraction motion.
While SIMT has the potential to reduce delivery and optimization times, it may not be suitable for
all target sizes and locations. As shown in Figure 41, the GI begins to increase as the target size becomes
smaller than approximately 10mm. With the improvement in MBMS v2.0, the threshold for GI degradation
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was reduced to target sizes below 8mm. For target sizes less than this threshold, the increased dose to
the normal tissues, corresponding to an increase in GI, may be deemed clinically unacceptable. In these
cases, there is the option to treat with stereotactic cones that are affixed to the linac gantry head. The
stereotactic cones can produce beam sizes down to 5mm in size with sharper penumbras compared to
MLCs, thereby improving the normal tissue sparing. Furthermore, if a Gamma Knife treatment unit, which
is a dedicated cranial SRS treatment machine, is available within the hospital system, then the small
lesions can be treated on that machine as well.
For these small lesions, it appears from Figure 41 that the MBMS plans have better ICIs than the
Gamma Knife, which may offset the benefits of the smaller GK GIs. However, the larger ICIs may be due
to the forward-based planning technique used to generate the Gamma Knife plans. The Gamma Knife
plans are typically created by manually designing a treatment such that the prescription isodose line
surrounds the contrast enhanced area of the MRI, which denotes the tumor location. The prescription
isodose line will cover the enhancement with some margin, typically 0.5-1.0mm. The target contour is
often drawn after planning is completed and is typically a contour of the enhanced area of the MRI.
Therefore, the prescription isodose is slightly larger than the target contour, which causes the increase in
the ICI.
The MBMS plans, however, are planned inversely, with the target contour drawn first, followed
by planning to have the prescription isodose volume cover the target contour as closely as possible. This
leads to optimal ICIs for the MBMS plans. This effect is amplified at smaller targets sizes, where the 0.51.0mm Gamma Knife margin will increase the prescription isodose size by a larger percentage, compared
with the larger targets. This difference in planning techniques, may also lead to slightly higher whole brain
V12Gy that were observed in the MBMS plans. Due to the difference in planning techniques used in this
study, the MBMS plans were not compared directly to the GK plans. Rather, the Gamma Knife plans were
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used as a basis for MBMS investigation, and the MBMS dose metrics (GI, ICI, and V12Gy) were used to
determine plan acceptability.
In addition to treating small targets with cones, there are instances where larger targets that are
next to critical structures, may not be suitable for MBMS optimized SIMT deliveries. The MBMS algorithm
creates plans with dynamic conformal arcs, where the MLC aperture conforms to the outside of the target.
This typically provides sufficient dose sculpting around most cranial targets. However, if the target is
particularly irregular or directly abutting a critical structure, additional MLC modulation for dose sculpting
may be required. For these targets, it may be beneficial to create separate VMAT plans, that allow for full
MLC modulation to improve the conformality of the dose to the irregular target or increase the dose
sparing of the critical structure.
Furthermore, a second VMAT plan may be warranted for single target that is located away from
a cluster of other targets. If the distal target was included in the MBMS plan, the isocenter of the plan
would move away from the primary cluster of targets to treat the distal target. This would amplify the
effect of rotational errors on the treatments. Introducing a second plan will help to keep the SIMT
isocenter close to the targets, thereby reducing errors from rotational uncertainties. Alternatively, an
additional margin could be added to the target contour to account for the rotational uncertainties. In
addition, if multiple targets exist throughout all areas of the brain, they could be separated into different
clusters based on location, and multiple SIMT plans could be used for treatment.
Due to the multiple treatment options for a cranial SRS patient, scheduling issues can arise
because the length of time required on the treatment machine may not be known until the plans are
finalized. This can often occur less than 24 hours prior to treatment. A single cranial SRS patient can take
anywhere between 30 minutes and 4 hours to treat, depending on the number and complexity of the
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plans. This can be logistically challenging to schedule on a clinical treatment machine that will likely be
treating other patients.

Figure 44: Decision tree for treating cranial SRS targets with a combination of single-isocenter multi-target
(SIMT), volumetric arc (VMAT), and stereotactic cones or Gamma Knife (GK) treatments.
Therefore, it is helpful to the clinical workflow to try and predict which modalities will be used for
treatment, prior to the patient receiving the therapeutic CT for planning. This can be done from looking
at their diagnostic brain MR images to determine the expected number, location, and size of the targets.
The target information can then be used to predict their expected course of treatment. A decision tree
for this process is shown in Figure 44. This decision tree does not contain mandatory rules for plan
selection, rather it should be used as a guideline.
Conclusion
The commissioning of the MBMS TPS system introduces unique challenges for physicists due in
part to the small fields, off-axis non-coplanar beam arrangements, and high-dose hypofractionated
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prescriptions. Advanced knowledge of these challenges along with the expected limitations of the MBMS
beam models can add familiarity to the commissioning process. Added familiarity will hopefully lead to
faster and more consistent MBMS commissioning across institutions.
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CHAPTER 7 CONCLUSION
The motivation for this work was to reduce the uncertainties in various subcomponents of the
IMRT commissioning-to-treatment paradigm with the overall goal of improving the accuracy of IMRT
deliveries. Five sub-components were selected for investigation that included:
1)

Radiation-imaging coincidence optimization on a Versa HD.

2)

Analyzing confidence limits used in AAPM task group no. 119.

3)

Investigating ion-recombination effects in PTW’s 1000 SRS.

4)

The inclusion of patient structures in IMRT QA calculations.

5)

IMRT single-isocenter multi-target cranial SRS commissioning.

Each sub-component affected only a fraction of modern IMRT deliveries, highlighting the
complexity and diversity of the treatments themselves. Although, unavoidably limited within the entire
scope of IMRT deliveries, the hope is that this research in the various sub-components, will enhance the
ability to treat within the therapeutic window by reducing the uncertainties in the delivered dose.
One of the most stressful and important tasks that a medical physicist will perform is that of the
initial commissioning of a treatment machine. The rarity of the task (a typical linac has a lifespan of 10+
years), coupled with the long-lasting effects that a mistake during commissioning will have on the lifetime
of the machine, makes this a potential major source of error in the clinic. In addition, commissioning of a
linac is often performed on a strict timeline that can be further compressed when upstream delays in linac
installation compress the commissioning schedule against a hard-set go-live date. Therefore, the work on
radiation-imaging coincidence optimization during the commissioning of a Versa HD has major utility for
the clinical physicist.
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The procedure that was developed provides step-by-step instructions on the optimizing the
radiation-imaging coincidence during the commissioning process. It also provides expected achievable
tolerances for the various sub-tasks involved in the procedure. This gives physicists clear direction of what
to do when calibrating the Versa HD and at what point to stop fine-tuning as additional effort would lead
to rapidly diminishing returns. This ensures that the machine will be calibrated with a high degree of
accuracy, without requiring an unrealistic amount of time. Time conservation during commissioning is
important as it allows the clinical physicist to focus their commissioning efforts in other areas. Ultimately
this procedure will not only reduce the uncertainties in the radiation-imaging coincidence calibration, but
it will also allow the physicist more time to reduce uncertainties in other areas as well.
The work on analyzing confidence limits used in TG-119 was able to shed light on the accuracy of
the simplified statistical assumption used to determine the confidence limits in the report. Due to general
application of the report for commissioning a wide range of treatment planning systems, any major
uncertainty in the analysis methodology used in the report, could have wide ranging implications for
clinical IMRT deliveries throughout Radiation Oncology. To validate the simplified statistical analysis used
in the report, a more advanced statistical analysis was used to model the data within the results.
Comparing the results between the complex and simple statistical analysis, it was found that the simplified
analysis was sufficiently accurate for the expected range of clinical data that would be used in the report.
This gave confidence that the simplified analysis of the TG-119 data could be performed, without the
added uncertainty of making a mistake while performing a more complex mathematical analysis.
Throughout the different stages of the IMRT commissioning-to-treatment process, physicists rely
on various measuring devices to query the radiation produced by the treatment machine. The
development of new treatment technologies will always be paralleled with new measuring devices to
quantify their accuracy. These devices typically display some results in an easy-to-digest format, however
the displayed results do not typically include an uncertainty analysis. Therefore, it is of utmost importance

111
for physicists to understand the uncertainties of the measuring devices, prior to use, and work to reduce
those uncertainties whenever possible.
PTW’s 1000 SRS measuring device employed a unique solution to improve the signal-to-noise ratio
in their detector arrays by using liquid filled detectors to improve the signal compared with traditional airfilled detector arrays. However, the liquid filled arrays have an inherent uncertainty due to the increased
loss of signal due to ion-recombination during the measurement. The effect of ion-recombination is
dependent on the strength and frequency of the radiation pulses exposed to the 1000 SRS, both of which
may change during an IMRT delivery. Therefore, the uncertainty in the measurement is not static, but will
change throughout the delivery, making it difficult to quantify for an individual measurement result.
The investigation of the 1000 SRS found that the uncertainty in the measurement due to ionrecombination could be dramatically reduced by appropriately calibrating the device on a per-plan basis
prior to use. The specific reference condition needed for the calibration, average dose rate, could be easily
extracted from the treatment plan and used for calibration. This simple calibration method gives the
physicist the ability to quickly reduce the uncertainties in their 1000 SRS measurements due to ionrecombination, thereby reducing the uncertainty when using the device in the commissioning and patientspecific IMRT QA process.
Patient-specific IMRT QA has the difficult task of querying the many different uncertainties in an
IMRT delivery, using a single measurement to determine whether the delivery is sufficiently accurate for
clinical use. Like most QA measurements, they are performed in a simplified geometry and use simplified
analysis technique to reduce the uncertainties in the QA itself. These simplified scenarios are typically void
of any patient-specific information that may be beneficial in determining whether a given QA result
represents a clinically acceptable treatment plan.
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The research to include structures in the IMRT QA calculations was an attempt to incorporate
patient-specific information into IMRT QA analysis. While the research was interesting, it became clear
that large amounts of data would be needed to draw a statistically significant conclusion of whether
including these structures would improve the correlation between IMRT QA results and the dosimetric
acceptability of the plan. Furthermore, the research focused on static-gantry deliveries that are decreasing
in popularity and being replaced by the more efficient moving-gantry volumetric arc therapy. Finally, the
way in which IMRT QA measurements are performed and analyzed has changed considerably, making the
initial research mostly obsolete. While the work may not have far reaching clinical importance, the
investigation itself highlighted many of the potential uncertainties in the IMRT QA and treatment
paradigm, particularly with the standard DICOM format used to store digital medical data, including that
which is used for IMRT deliveries.
Perhaps the greatest test of IMRT delivery accuracy is that of SRS. A typical fractionated IMRT
delivery benefits from the gaussian-smoothing effect, where multiple treatment deliveries occur with
some uncertainty around a mean value, and it is expected that they will average to something close to
the mean. Conversely, SRS has no such benefit of averaging, and any uncertainty in the single treatment
fraction will have direct impact on whether the patient’s treatment falls within the therapeutic window.
Furthermore, single-isocenter multi-target (SIMT) cranial SRS has its own unique challenges that are not
present in typical IMRT treatment. In a typical IMRT treatment, a single unified target contour is treated
with the planned isocenter placed close to the centroid of the target. However, the multi-target nature of
SIMT deliveries necessitates that the isocenter is placed outside of at least one of the targets.
The inherent lack of gaussian-smoothing and the irregular placement of isocenter outside the
target amplified the importance of the research on commissioning Brainlab’s SIMT cranial-SRS TPS for the
Versa HD. The research presented in this chapter, outlines the work needed to commission, validate, and
ultimately treat with this modality. In addition, it highlights some of the unique obstacles and solutions in
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SIMT commissioning. The hope is that the work presented can be used by future clinics during
commissioning, thereby reducing their commissioning uncertainties.
Although this research covered five different topics in various areas on IMRT, there were reoccurring common themes. Throughout the research, data was transferred between the various systems
using the DICOM format. On DICOM import, most systems would convert the data into their own internal
format for ease of use, speed, and efficiency. So too did the custom built Matlab code convert the DICOM
data into usable DICOM data types. As new or upgraded systems emerge, the system-specific file types
are expected to evolve to suit the needs of the systems.
However, given the historical inertia of the DICOM format, one could expect it to remain relatively
the same, acting as the common language between the various systems. Although the DICOM format can
often be used to transport data between systems, there is no guarantee that when the data is transferred,
the information will be well-preserved. Throughout this research it was found that data transfer could
lead to missing information, unreal information (ex. negative dose), and potentially worst of all, slightly
incorrect information (ex. 1.40Gy rounded to 1.00Gy). Therefore, it is crucial to know how each system
handles the import and export of DICOM data to detect potential errors and uncertainties that may exist
in the IMRT process due to this data transfer.
This understanding of data transfer should be built into the commissioning process of any new
equipment or technology. One could be tempted to assume that a clinically produced technology would
perform with an exceptionally high accuracy all the time. In reality, most new technologies will have
limitations, approximations, and possibly anomalies that make them behave with inherent uncertainties.
Whether it is the ion-recombination effect of the 1000 SRS, the residual radiation-imaging isocentricity
drift of the Versa HD, or the modeling error in the Brainlab Elements TPS, any new technology should be
well vetted and independently investigated by the medical physics community. It is critical that both
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positive and negative experiences are shared, to build confidence in the accuracy of treatment and
prevent the propagation of errors.
While highlighting uncertainties in different systems is useful, it is important to remember that is
easier to find instances where a system fails compared to showing that it works for a wide variety of cases.
As was the case with the gamma index, where previous publications showed that gamma index pass rates
did not correlate with patient specific plan metrics for head and neck plans. Their experiment was
repeated to replicate, and improve on, their intriguing results, however in contrast to their findings a good
correlation between gamma index pass rates and patient specific plan metrics was found for a standard
clinical analysis criterion. However, this did not vindicate the pass rate as it only showed a good correlation
for a small subset of the clinical IMRT setups for which the gamma index would be applied. To prove a
universally strong correlation would have required much more data that covered different types of IMRT
deliveries to different body sites.
What these seemingly conflicting results does show is that no single detector or analysis
technique is perfect, and they all have their areas in which they perform better. Then the issue arises as
to how a clinical physicist can be sure that a measurement is accurate. This is of particular importance
during commissioning when uncertainties in measurements will propagate through the lifetime of the
machine. The solution follows the technique that was best seen in the SIMT research when multiple
detectors were used to measure the same field. Leveraging the utility of multiple redundant technologies,
whenever possible, will help prevent the technology-specific uncertainties from effecting clinical IMRT
deliveries.
Using multiple technologies for IMRT measurements may reduce uncertainties, however it
requires additional physics effort and possibly equipment costs. Therefore, it is useful to know when it
would be most prudent to employ additional effort to reduce uncertainties. This leads to the common
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theme of standardization. Standardization is typically approached when enough different groups have
performed the same task that they can now combine their cumulative experiences to generate best
practices for that task. This highlights the importance of publishing commissioning experience like what
was done with the radiation-imaging coincidence adjustment and SIMT commissioning work on the Versa
HD. Publication of this work to an external audience also allows for global peer review that can often lead
to suggestions that improve the publishers practice as well.
The peer review of a department clinical practices is possibly the best tool for reducing
uncertainties in IMRT deliveries. It leverages the power of the community of medical physicists to tackle
the implementation of the ever-expanding list of software, technologies, and treatment techniques used
for IMRT. As IMRT deliveries continue to develop, physicists should continue to research and evaluate the
new deliveries and the technologies that support them, to reduce IMRT delivery uncertainties and provide
accurate, high quality care for radiotherapy patients.
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APPENDIX A COMPUTER CODING IN MEDICAL PHYSICS
Introduction
The use of computer coding was integral throughout much of this work. The primary coding
language used was Matlab, however there are many coding applications and languages that are used
within Medical Physics. The one common element, which connects these languages together, is the
standard format used to store digital medical information known as the Digital Imaging and
Communications in Medicine or DICOM format. The DICOM format was created through a joint venture
between the American College of Radiology and the Natural Electrical Manufacturers Association in the
mid-1980s. The goal was to create a standard template for storing various types of medical information,
so that this information could be easily passed between systems. There are multiple types of DICOM files,
which outline the storage of image information (computed tomography scans, magnetic resonance
images, radiographs, etc.), patient structure information that is drawn in the planning system, dose files,
as well as radiotherapy plan information. This appendix will outline the general structure of the DICOM
format, then it will focus on the specific DICOM files that were used in this research, and finally it will go
over the methodology for some of the computer code that was developed throughout this work.
DICOM files are structured similar to a book, with a title page, chapters, and sub-chapters that
contain the relevant information. The title page consists of a preamble and a header, which denotes the
type of the DICOM file and contains the relevant patient information for the file. The chapters and subchapters within the files contain what is known as the DICOM Data Elements. Each of the DICOM Data
Elements are labelled with a specific tag, followed by the length of the element, and finally followed by
the data within the Element. Depending on the type of the DICOM file, it may also contain a value
representation or VR in between the tag and element length, which denotes the data type of the element.
To find data within the DICOM file, software will look for the specific tag, which consists of a pair of 16-bit
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unsigned integers for a total length of 32-bits. The tags are commonly written as (HHHH,hhhh) where each
H and h is a 4-bit hexadecimal number. For example, the tag for gantry angles is (300A,011E). When trying
to find gantry angle for a specific control point, the software will look for the (300A,011E) tag, read the VR
if it exists, check the length of the DICOM Data Element which represents the gantry angle, and then read
the data. As each plan will contain multiple control points, the (300A,011E) will appear multiple times
within the file for each control point that is nested within the radiation beams. To summarize, when
writing code to look through a DICOM file, the element lengths should be used to skip through the file
until the desired tag is located, the VR should be checked (if it exists), after which the length of the element
should be checked and then the data should be extracted.

Figure 45: Converting DICOM Data Element tags from hexadecimal to 8-bit.
During the initial stages of the research, the version of Matlab that was used did not have a
specific function to automatically look through the DICOM files, so it was necessary to write code to open
the files and extract the relevant information. The custom code started by opening the file with a
hexadecimal to 8-bit converter. Converting the file to 8-bit from hexadecimal meant the previous tags
which were represented by a pair of 16-bit unsigned integers, were now represented by four 8-bit
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unsigned integers. The conversion for the hexadecimal gantry angle tag of (300A,011E) to the 8-bit [10 48
30 1] is show in Figure 45.
After opening the DICOM file in 8-bit format, the code would skip the preamble and header and
go directly to the DICOM Data Elements. The first tag was checked to see if it contained information that
was relevant to the research. If it did not, the code would read the length of Data Element and skip ahead
by that many bits. If it contained relevant information, then the data would be captured. Table 14 is a list
of relevant DIOCM Data Elements tags that were used in this research. It is important to note that this
Matlab code would be greatly simplified if it were done today using the dicomread.m function. The
dicomread.m is a built-in Matlab function that opens a DICOM file and sorts all DICOM data in an easy-tomanipulate array. This would drastically reduce the amount of code necessary to perform the work.
Tag
(hexadecimal)
Tag (8-bit)
Name
DICOM Filetype
(300A,011E)
[10 48 30 1]
Gantry Angle
Rt Plan
(300A,00C2)
[10 48 194 0]
Beam Name
Rt Plan
(300A,0120)
[10 48 32 1]
Beam Limiting Device Angle
Rt Plan
(300A,0122)
[10 48 34 1]
Patient Support Angle
Rt Plan
(3008,00A0)
[8 48 160 0]
Beam Limiting Device Leaf Pairs Sequence
Rt Plan
(3008,0078)
[8 48 120 0]
Start Meterset
Rt Plan
(3008,007A)
[8 48 122 0]
End Meterset
Rt Plan
(3008,0040)
[8 48 64 0]
Control Point Delivery Sequence
Rt Plan
(300A,00C0)
[10 48 192 0]
Beam Number
Rt Plan
(300A,011C)
[10 48 28 1]
Leaf/Jaw Positions
Rt Plan
(300A,0110)
[10 48 16 1]
Number Of Control Points
Rt Plan
(300A,010E)
[10 48 14 1]
Final Cumulative Meterset Weight Attribute
Rt Plan
(3006,0022)
[6 48 34 0]
ROI Number
RT Structure
(3006,0026)
[6 48 38 0]
ROI Name
RT Structure
(3006,0050)
[6 48 80 0]
Contour Data
RT Structure
(3006,0084)
[6 48 132 0]
Referenced ROI Number
RT Structure
(0020,0032)
[32 0 50 0]
Image Position
Rt Dose
(3004,000E)
[4 48 14 0]
Dose Grid Scaling
Rt Dose
(7FE0,0010)
[224 127 16 0]
Pixel Data
Rt Dose
Table 14: List of relevant DICOM Data Element tags in both hexadecimal and 8-bit formats, along with
names and DICOM file types in which they are located.
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Although Matlab code was used throughout most of the presented research, the gamma index
work required the most amount of code. Furthermore, the code required the most amount of creative
solutions, as it dealt will large amounts of data that would often overwhelm the memory of computers
that were executing the code. Therefore, the following paragraphs will focus on the structure and
obstacles of the Gamma Index code, while an overview of the code used in the other research is provided
in their individual chapters.
As described in Chapter 5, the goal of the gamma index research was to include patient-specific
anatomical structures in plan-specific gamma index calculations. To approach the coding for this research
it was broken into three parts:
1) Structure data extraction from the DICOM files and projecting the structures from a beams-eyeview onto the dose plan used for the gamma index calculation.
2) Performing a gamma index calculation
3) Perform a correlation analysis between the passing rates of the gamma calculations and the
patient specific plan deviation metrics.
This appendix will focus on the extraction of the structure data as it was unique to this research.
To begin the extraction of the structure data from the DICOM files, the file was opened and converted to
8-bits from hexadecimal. The code searched the file to find the number of contours, the names of the
contours, and the contour data itself. The code would then prompt the user to select which contours
should be extracted for analysis. In the context of this research, the two contours that were to be included
in the gamma index calculation were the PTV and spinal cord. However, due to the lack of standardization
in naming conventions, the various plans could have different names for the same structure. For example,
spinal cord could be named: spinal cord, cord, spinalcord, or spine. Therefore, it was necessary to have
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human input to the otherwise automated code to distinguish the structures from the different contour
names.
Once the contour numbers, corresponding to the spinal cord and PTV, were manually selected,
the code extracted the contour data for those structures. In the DICOM format, the contour data is
represented as a set of 3-Dimensional coordinates that delineate the outside borders of the contours. The
coordinates are grouped by axial planes of the image set. Therefore, each set of contour points describe
the vertices of a shape on a given axial plane. By combining the 2D-shape across all the axial slices of the
image, a 3-dimensional shape is formed.
The 3-Dimensional coordinates in DICOM structure files are given relative to the 3-Dimensional
coordinate of the upper left-hand corner of the associated image. While this coordinate convention is
practical for DICOM files, for this research it was more beneficial to describe the contours in relation to
the central axis of the plan, which corresponds to isocenter in the treatment vault. Ultimately the goal
was to create beams-eye-view projections of the contours, which are centered about isocenter.
Translating the coordinates system so that the central axis of the plan was the origin of the coordinate
system, allowed the easy application of mathematical rotations which describe the beams-eye-view
rotations around isocenter. To perform this translation, the DICOM isocenter location for each plan was
subtracted from the contour coordinates, thereby centering the coordinate system at the central axis of
the plan.
After performing the coordinate shift, the length of the spine contour was reduced to only occupy
the same axial slices as the PTV. This was done to increase the speed of the code and reduce the memory
burden of calculations, particularly when it came to rotating the structures. By reducing the length of the
spine contour to only occupy the same axial slices as the PTV, the matrix size needed for the rotation was
reduced. The power of Matlab as a programming software is in its ability to manipulate matrices and as
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such, matrices were leveraged throughout the code in this research. When performing rotations with
matrices it is necessary to allocate enough space in the rotated matrix to make sure the object that is
being rotated does not get “lost” outside of a matrix. The size of the matrix necessary to prevent this loss
is equal to the Euclidian distance between the farthest contour point and the center-point of rotation
(central axis of the beam at isocenter). For the head and neck plans used in this study, the spine was
typically contoured all the way to the inferior border of the CT, well outside the treatment fields that
would ultimately be used in the gamma index calculation. Therefore, reducing the length of this contour
would have no effect on the calculation, while aiding in memory conservation and calculation time
efficiency.
With the structure data extracted from the DICOM Rt Structure file, the next step in the code was
to extract the gantry and couch angles for each beam and used them to create rotation matrices to align
the contours in the beams-eye-view projections of the fields. The IMRT QA that was being investigated in
this study is typically performed at gantry and couch angles of zero degrees. Therefore, rotations were
needed to transform the structure coordinates from the beams-eye-view projection to the zero-angle
setup for IMRT QA. In terms of cartesian coordinates, this would align the beams-eye-view of the contours
along the z-axis as shown in Figure 46.
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Figure 46: In-room coordinate system used for structure rotations in the Matlab code.
The treatment angles for each beam were found by looking through the DICOM RT Plan file for
the appropriate DICOM tag and extracting the values. Rotational matrices were created based on the
angles and the in-room coordinate directions. Matrix multiplication is non-commutative, so it was very
important to perform the rotations in the correct order. The correct order for the rotations was couch,
followed by gantry. Collimator rotations were not performed as the IMRT QA dose planes were calculated
at their planned collimator angles. Gantry rotations were performed around the x-axis (Figure 46), and
couch rotations were performed around the z-axis (Figure 46). The matrices used to calculated the beamseye-view structure coordinates (𝑃⃑′ ) from the DICOM structure coordinates (𝑃⃑𝑜 ,) using gantry (𝜗), and
couch angles (𝛾) are shown in Equation 17.
With the coordinates transformed into beams-eye-view projections, the poly2mask function was
used to create a 3-dimensional high-resolution matrix with ones inside of the contours and zeros outside
of the contours. To save memory space, the matrix was created with the data type uint8. Matlab will
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automatically create matrices with a double-precision floating-point value type which occupies 64bits of
memory per entry, while uint8 only occupies 8 bits, allowing the high-resolution memory allocation to be
reduced by a factor of eight.
𝑃⃑ ′ = 𝑅⃑𝑔𝑎𝑛𝑡𝑟𝑦 𝑅⃑𝑐𝑜𝑢𝑐ℎ 𝑃⃑𝑜 , where
𝑥𝑜
𝑃⃑𝑜 = [𝑦𝑜 ]
𝑧𝑜
cos 𝜗
𝑅⃑𝑔𝑎𝑛𝑡𝑟𝑦 (𝜗) = [ 0
− sin 𝜗
cos 𝛾
𝑅⃑𝑐𝑜𝑢𝑐ℎ (𝛾) = [ sin 𝛾
0

0
1
0

sin 𝜗
0 ]
cos 𝜗

− sin 𝛾
cos 𝛾
0

(17)

0
0]
1

Finally, the x-y planes of the 3-Dimensional matrix were combined to effectively “add” the
structures in the beams-eye-view. The planes were combined by interpolating each plane to the final
resolution of the DICOM dose fields that were to be used in the gamma analysis (0.586mm/pixel). Each
interpolation included a scaling factor for the structures that account for the divergence of the beam. The
final result of all these calculations, were 2-dimensional matrices that contained the thickness of the spinal
cord and PTV structures at each point in the beam, with the matrices centered on the central axis of the
field.
The code was created and tested in an object-oriented fashion, however to evaluate the overall
end-to-end process, a simple test case was created. This test case consisted of two offset box contours,
with dimensions of (2cm x 4cm x 2cm). Three fields were created with different couch and gantry rotations
(Figure 47).
For each of the fields, the four structure edges were calculated and compared to the expected
values. The average difference between calculated and expected edges was 0.41mm +/- 0.16mm. These
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inaccuracies come from the limitations in pixel size and the contour generations from the finite set of
axial-shape coordinates in the DICOM structure files.

Figure 47: Test fields and structures used to perform end-to-end testing on structure rotation Matlab
code.
Pixel sizes were one of the main limitations of this research in that there were constant tradeoffs
between accuracy and memory (which sometimes went hand in hand with speed). The manipulation of
contours was extremely difficult. The programming solution that was selected was designed to take
advantage of the matrix-manipulation functions in Matlab. However, this meant that the matrices had to
be large enough to cover the structures while they rotated in three dimensions and large enough to
maintain a high resolution. Throughout the coding process, internal functions were built to down sample
the matrix size and save memory by using different data types (float, int8, etc.) to lower the bit-per-pixel.
Although the Matlab solution produced a workable solution for research, due to the memory issues, it is
recommended that any clinical implementation of this research would use a different programming
technique that may involve a different language.
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Introduction: The treatment of cancer using intensity modulated radiation therapy (IMRT) is
complex, involving many sub-processes to commission a treatment platform and treat patients.
Uncertainties within the individual sub-process can lead to inaccurate treatments and sub-optimal patient
outcomes. This research focused on minimizing uncertainties throughout IMRT commissioning and
treatments. Methods: Five sub-processes were selected for uncertainty reduction: 1) optimizing
radiation-imaging coincidence of the treatment machine, 2) improving the statistical model used to
analyze IMRT commissioning data, 3) reducing the effect of ion recombination in IMRT quality assurance
measurements, 4) improving the correlation between IMRT quality assurance results and patient-specific
delivery inaccuracies, 5) commissioning of cranial stereotactic radiosurgery treatments. Results:
Uncertainty reduction was achieved in all five sub-processes. Although the effect of this work on any single
patient’s treatment is difficult to quantify, it is expected that the improvement in the sub-process accuracy
will have a beneficial effect on the overall IMRT treatment delivery accuracy. Conclusion: Reducing
uncertainties is an important aspect of radiotherapy quality assurance and should continue to be
investigated for current and future treatment techniques.
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